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The SRC-family kinase LYN is highly expressed in tri-
ple-negative/basal-like breast cancer (TNBC) and in
the cell of origin of these tumors, c-KIT-positive
luminal progenitors. Here, we demonstrate LYN is a
downstream effector of c-KIT in normal mammary
cells and protective of apoptosis upon genotoxic
stress. LYN activity is modulated by PIN1, a prolyl
isomerase, and in BRCA1 mutant TNBC PIN1 upre-
gulation activates LYN independently of c-KIT.
Furthermore, the full-length LYN splice isoform (as
opposed to the Daa25–45 variant) drives migration
and invasion of aggressive TNBC cells, while the ratio
of splice variants is informative for breast cancer-
specific survival across all breast cancers. Thus,
dual mechanisms—uncoupling from upstream sig-
nals and splice isoform ratios—drive the activity of
LYN in aggressive breast cancers.INTRODUCTION
Breast cancersmolecularly classified as basal-like breast cancer
typically display the triple (ER/PR/HER2)-negative (TNBC)
phenotype (Badve et al., 2011). The molecular etiology of spo-
radic TNBC is still poorly understood, although germline
BRCA1 mutations predispose to TNBC, and BRCA1 silencing
or dysfunction in the BRCA1 pathway can be found in sporadic
TNBC (Badve et al., 2011). Limited therapeutic options are avail-
able for TNBC; chemotherapy is often initially beneficial, but
TNBC has a high risk of relapse (Liedtke et al., 2008), empha-
sizing the need to elucidate its biology and identify targets for
novel treatment options.
The mammary epithelium consists of luminal cells, including
ER-negative (ER) progenitor-like and ER-positive (ER+) differ-
entiated cells, and basal cells. TNBC likely originates from
luminal ER progenitors, and the gene expression profile of
both BRCA1 mutation-associated and sporadic TNBC reflects3674 Cell Reports 25, 3674–3692, December 26, 2018 ª 2018 The A
This is an open access article under the CC BY license (http://creativea luminal progenitor-like profile (Lim et al., 2009; Molyneux
et al., 2010). Elucidating the molecular regulation of this cell sub-
set is important to understand not only the normal mammary cell
homeostasis but also the origins of TNBC.
Mammary ER luminal progenitors are characterized by
expression of the membrane tyrosine kinase receptor c-KIT
(Regan et al., 2012; Smart et al., 2011), which is required for
growth and survival of these cells (Regan et al., 2012; Tornillo
et al., 2013) as well as the SRC family tyrosine kinase (SFK)
LYN (Bach et al., 2017; Regan et al., 2012; Smart et al., 2011),
a known effector of c-KIT signaling in hematopoietic cells (Shi-
vakrupa and Linnekin, 2005). Other SFKs are expressed in the
mammary epithelium, but other than LYN, only FYN has an
expression pattern restricted to a specific population (basal
epithelial cells) (Bach et al., 2017; Kendrick et al., 2008). Based
on this co-expression, a c-KIT-LYN signaling axis in mammary
epithelial progenitors is proposed.
Previous studies have largely focused on LYN function in
hematopoietic cells and leukemia, and persistent activation
and/or deregulation of LYN has been associated with imatinib
resistance in BCR-ABL+ leukemia (Wu et al., 2008). In breast
cancer, LYN has been reported as overexpressed and a poten-
tial drug target in TNBC by several studies (Choi et al., 2010;
Hochgra¨fe et al., 2010; Molyneux et al., 2010; Regan et al.,
2012; Smart et al., 2011). LYN point mutations in breast cancer
are rare (0.6%) (https://cancer.sanger.ac.uk/cosmic), but have
been associated with anti-estrogen resistance in a subset of
ER+ tumors (Schwarz et al., 2014); only 6%–10% of breast can-
cers show LYN amplification (http://www.cbioportal.org/index.
do; https://cancer.sanger.ac.uk/cosmic). Other mechanisms
contributing to the underlying LYN dysregulation in TNBC remain
to be defined, as does the potential wider role of LYN in breast
cancer.
Here we demonstrate that LYN kinase is a transducer of c-KIT
growth signals in the normal mammary epithelium.We show that
LYN can also be activated by prolyl isomerase 1 (PIN1), normally
transcriptionally repressed by BRCA1. In BRCA1-deficient
TNBC, loss of this transcriptional repression results in increased
PIN1 levels and thus in LYN activation independently of c-KIT.
Furthermore, we address the role of the two LYN splice isoformsuthor(s).
commons.org/licenses/by/4.0/).
(legend on next page)
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in breast cancer and find that only full-length LYN (LYNA), as
opposed to LYND25–45 (LYNB), promotes cell migration and inva-
sion. LYNA is expressed more highly in TNBC than other breast
cancer types; however, we find that a higher ratio of LYNA over
LYNB is present in breast cancers of patients with shorter sur-
vival times, irrespective of tumor subtype. Therefore, our findings
demonstrate dual mechanisms, uncoupling from upstream sig-
nals and changing splice isoform ratios, driving the activity of
LYN in aggressive breast cancers. These mechanisms have
the potential to be targeted therapeutically, and the LYNA::B ra-
tio is a biomarker that could identify patients who would benefit
from such interventions.
RESULTS
LYN Kinase Is Regulated by c-KIT and Promotes Growth
of Normal Mammary Epithelial Cells
To define themajor components of the c-KIT signaling network in
the mammary epithelium, we examined expression of c-KIT and
its ligand stem cell factor (SCF) in normal mouse mammary cell
populations (Figure 1A). The two splice variants of c-KIT,
GNNK+,and GNNK, were expressed primarily in luminal cells
(particularly in the ER luminal subpopulation) (Figure 1B). The
two SCF isoforms, soluble SCF (sSCF) and membrane-bound
SCF (mSCF), were present at low levels in luminal cells, whereas
basal cells showed the highest levels of total SCF, with almost
exclusive expression of the sSCF form (Figures 1B and 1C).
LYN is a key effector of c-KIT signaling in hematopoietic cells,
and LYN expression and c-KIT expression in themammary gland
are correlated (Regan et al., 2012; Roskoski, 2005). LYN exists in
two isoforms, LYNA (full-length LYN) and LYNB (LYND25–45) (Fig-
ure 1D). When expression of these isoforms was analyzed by
semiquantitative RT-PCR, both LynA and LynB were found in
all mammary epithelial populations; however, there was an asso-
ciation between higher LynA and c-Kit expression in the luminal
ER compartment (Figure 1B). Therefore, the expression pattern
of c-KIT, SCF, and full-length LYN in the mammary epithelium
indicated the existence of a basal-to-luminal paracrine c-KIT
signaling network, mediated by the soluble form of SCF
(sSCF), along with an enrichment of a potential c-KIT effector,
LYN, in the SCF-responsive luminal cells.Figure 1. LYN Is Positively Regulated by c-KIT in Normal Mammary Ce
(A) Flow cytometry of primary mammary cells stained with CD45, CD24, and Sca
cells (bottom plot) were gated to define basal (CD24+/low Sca-1, red), luminal
epithelial cell populations.
(B) Expression pattern of c-Kit, Scf, and Lyn splicing transcripts in mouse mamm
independent isolates (four mice for each). Amplicons of the expected size using p
used as a control.
(C) qRT-PCR gene expression analysis of Scf in mouse mammary cell population
(sSCF) only. Data are from two independent isolates (four mice for each), presen
(D) Schematic of LYN isoforms showing the 21-amino acid insertion (black resid
(E) Representative western blot analysis and quantitation of c-KIT, JAK2, STAT3, A
mammary organoids cultured on Matrigel and stimulated with SCF for the indica
(F and G) Representative western blot analysis and quantitation of LYN autophosp
extracts (G) from primary mouse mammary organoids cultured on Matrigel and s
(H and I) Western blot of c-Kit expression and LYN autophosphorylation (Y397) in
c-Kit knockdown (shKit1 and shKit2) lentiviruses (H) or following treatment with c-
Unless otherwise stated, blots are representative of three independent experimen
time 0). *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S1.
3676 Cell Reports 25, 3674–3692, December 26, 2018To determine the signaling cascade activated by c-KIT, we
treated primary mouse mammary epithelial cells with SCF and
assessed the phosphorylation status of a series of previously
described c-KIT effectors (Roskoski, 2005). Addition of SCF
caused a marked increase in c-KIT phosphorylation, as well as
upregulation of phosphorylation levels of JAK2, STAT3, AKT,
and ERK1/2 with distinctive kinetics (Figure 1E). Phosphorylation
levels of LYN at its positive regulatory site Y397 were elevated
approximately 6-fold within 60 min of stimulation with SCF (Fig-
ure 1F), and SCF treatment induced an increase in LYN kinase
activity as measured by an immunoprecipitation (IP) kinase
assay (Figure 1G). Conversely, c-KIT inhibition, by using short
hairpin RNA (shRNA) against c-KIT or a specific anti-c-KIT block-
ing antibody (ACK2), led to a significant decrease in LYN phos-
phorylation (Figures 1H and 1I; Figure S1A).
Because c-KIT is required for growth of normal mammary
cells in vitro (Regan et al., 2012) and positively regulated LYN
activity, we tested whether LYN depletion also affected mam-
mary cell growth. Following Lyn knockdown with two distinct
shRNAs (shLyn1 or shLyn2) (Figure 2A), primary mouse mam-
mary epithelial cells exhibited defective growth (Figure 2B)
and a significant reduction in the expression of the proliferation
marker Ki67 (Figure 2C). This effect was observed both in un-
sorted primary mammary epithelial cells and in the purified
luminal ER progenitor population (Figures 2D and 2E; Fig-
ure S1B). Furthermore, knockdown of LYN in the human normal
mammary epithelial cell line, MCF10A, with two distinct
shRNAs caused a significant reduction in relative cell growth
and in Ki67 expression compared to shScrambled (shScr) con-
trols (Figures 2F and 2G), without obviously affecting acinar ar-
chitecture (Figure S1C).
We next tested the ability of a constitutively active LYN
(Y508F) mutant to rescue c-KIT knockdown. Whereas overex-
pression of wild-type LYNA (LYNA WT) had no effect on the
viability of c-KIT knockdown cells, constitutively active LYN
(LYNA CA) rescued the growth defect (Figure S2A). In addition,
when we examined the ability of LYN-depleted cells to activate
c-KIT downstream effectors in response to SCF, we found that
LYN knockdown specifically interfered with AKT phosphoryla-
tion upon c-KIT stimulation (Figure S2B). Overall, these findings
support the model that c-KIT activates LYN kinase to transducells
-1 antibodies. CD45+ leukocytes (purple) were gated out (top plot), and CD45
ER (CD24+/high Sca-1, green), and luminal ER+ (CD24+/high Sca-1+, blue)
ary cell populations. Semiquantitative RT-PCR data are representative of two
rimers spanning the alternative exon for each gene are indicated. Gapdh was
s using probes for both total Scf (membrane bound and soluble) or soluble Scf
ted as relative expression levels with leukocytes as the comparators.
ues) in the N-terminal domain of LYNA.
KT, and ERK1/2 phosphorylation levels in protein extracts from primary mouse
ted times. Tubulin was used as loading control.
horylation (Y397) (F) and immunoprecipitation (IP) LYN kinase assay of protein
timulated with SCF for 0, 15, 30, and 60 min.
primary mouse mammary organoids after transduction with control (shScr) or
KIT blocking (ACK2) or immunoglobulin G (IgG) isotype (IgG Ctr) antibodies (I).
ts (mean and SD; two-tailed unpaired t tests) (in E and F, t tests are relative to
(legend on next page)
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pro-growth and survival signals and activate the AKT pathway in
mammary epithelial cells.
LYN Is Required for Growth of BRCA1-Deficient
Mammary Tumor Cells
We have previously demonstrated that Brca1 mutation-associ-
ated breast cancers originate from luminal ER progenitors (Mo-
lyneux et al., 2010) and that c-KIT and LYN are expressed in
mouse Brca1 mammary tumors (Regan et al., 2012). To deter-
mine whether Brca1 mutant cell growth depends on the activa-
tion of the c-KIT signaling pathway, primarymouseBrca1mutant
mammary tumor cells transduced with lentiviruses expressing
either one of two shRNAs against c-Kit (shKit1 and shKit2) or a
control shRNA (shScr) were analyzed. Despite reduced c-Kit
expression, no change in cell growth was observed in shKit cells
compared to shScr cells (Figure S2C). Furthermore, unlike
normal cells, c-Kit-depleted tumor cells had phospho-LYN levels
similar to those of control cells (Figure S2D) and treatment of
Brca1 tumor cells with the ACK2 c-KIT blocking antibody did
not alter LYN phosphorylation status (Figure S2E; contrast with
Figure 1I). Likewise, c-KIT knockdown failed to affect phos-
pho-LYN levels in three human c-KIT-positive breast cancer
cell lines with low BRCA1 levels: HCC38 (BRCA1 silenced by
methylation), HCC1806, and MDA-MB-157 (BRCA1 low due to
downregulation by microRNA [miRNA]) (Garcia et al., 2011; Li
et al., 2013) (Figure S3A). However, c-KIT knockdown in a
c-KIT-positive BRCA1-wild-type cell line, HCC1187, suppressed
LYN phosphorylation (Figure S3A). These results indicate that in
Brca1/BRCA1 tumor cells, at least in vitro, c-KIT is dispensable
for growth and does not regulate LYN activity.
Next, we evaluated the effects of LYN knockdown onBrca1 tu-
mor cell growth. LYN knockdown markedly impaired growth of
mouse Brca1 tumor-derived cells in monolayer culture (Fig-
ure 3A) and in three-dimensional (3D) culture conditions on
Matrigel (Figure 3B). Staining of 3D-cultured tumor cells for the
proliferation marker Ki67 showed that the number of proliferating
cells was reduced by approximately 30% in shLyn-transducedFigure 2. LYN Promotes Normal Mammary Cell Growth
(A) Analysis of Lyn expression levels by qRT-PCR relative to shScr cells (top) a
transduction with control (shScr) or Lyn knockdown (shLyn1 and shLyn2) lentivir
(B) Growth of mammary organoids after transduction with control (shScr) or Lyn k
(left bottom panel) or organoid size (right bottom panel) relative to shScr cells, day
culture. Scale bar, 75 mm.
(C) Ki67 immunofluorescence staining (green) of control (shScr)- and shLyn-ca
counterstaining). Representative images and quantification of the percentage of
(D) Colony-forming potential of unfractionated primary mammary epithelial cells (a
from each fraction were plated on Matrigel, and colony numbers were determine
(E) Growth inhibition of unfractionated primary mammary epithelial cells (all ep
knockdown (shLyn1 and shLyn2) lentiviruses and seeded onto Matrigel. Cell gr
100 mm); quantitation, right.
(F) Growth inhibition of MCF10A cells transduced with lentiviral vectors carrying c
cells were grown in 3D on Matrigel, and relative cell numbers were assessed after
from shScr, shLyn1, or shLyn2 cells are shown (scale bar, 100 mm), together with
(GAPDH loading control).
(G) Confocal microscope analysis of Ki67 immunofluorescence-stained shScr,
quantitation. DAPI was used for counterstaining. Scale bar, 20 mm.
Blots are representative of three independent experiments. Quantitation, mean an
quantitative real-time RT-PCR (mean ± 95% confidence intervals; significance o
dependent experiments for each of 3 technical replicates per sample) (Cumming
3678 Cell Reports 25, 3674–3692, December 26, 2018cultures compared with control (Figure 3C). The kinase activity
of LYN was required for its pro-survival functions, because
expression of shRNA-resistant wild-type LYNA (LYNA*WT) was
able to rescue the effect of shLyn transduction, but expression
of a kinase-dead LYNA (T410K) mutant (LYNA*KD) was unable
to do so (Figure 3D). The broad spectrum kinase inhibitor
Dasatinib, which was able to block LYN Y397 phosphorylation
in mammary epithelial cells in a dose-dependent manner (Fig-
ure S3B), inhibited growth of three mouse BRCA1 tumor-derived
cell lines (half-maximal inhibitory concencetration [IC50] 0.1–
1 mM) and the human BRCA1 mutant HCC1937 line (IC50
0.1 mM) (Figures S3C and S3D).
Use of two short hairpins targeting human LYN (Figure 3E)
demonstrated that LYN knockdown in human breast cancer cells
also significantly impaired cell growth in the BRCA1-mutated
HCC1937 human breast cancer cell line (Figure 3F) and in cells
from a BRCA1 mutant breast cancer patient-derived xenograft
(PDX) (Figure 3G). These effects, therefore, were consistent in
both mouse and human cells.
Because LYN blockade effectively suppressed tumor cell
growth in vitro, we next evaluated the effects of blocking LYN
activity in vivo. Intraperitoneal (i.p.) injection of Dasatinib strongly
reduced LYN phosphorylation in the normal mammary epithe-
lium of wild-type mice (Figure S3E), and daily treatment with
Dasatinib significantly inhibited growth of BlgCre Brca1fl/fl
p53+/ tumors (Figures S3F and S3G). Immunohistochemical
staining for phospho-histone H3 (phospho-H3) showed a lower
number of mitotic cells in Dasatinib-treated compared to
vehicle-treated tumors (Figure S3H).
Reduction of cell numbers following constitutive Lyn knock-
down made testing the effects of specific Lyn depletion by
shRNA on tumor cell growth in vivo difficult. Therefore, a condi-
tional Lyn knockdown system in which mouse Brca1 tumor cells
expressed shRNA against Lyn under the control of doxycycline
was established. Analysis of Lyn transcript levels after exposure
to doxycycline confirmed that Lyn expression was reduced in
inducible shLyn-carrying cells in the presence of doxycyclinend western blot (bottom) in primary mouse mammary organoids 4 days after
uses.
nockdown (shLyn1 and shLyn2) lentiviruses, assessed by cell number change
4 after plating. Top panels: representative images show organoids at day 6 of
rrying mammary organoids 6 days after lentiviral transduction (DAPI nuclear
Ki67-positive cells. Scale bar, 20 mm.
ll epithelial) or basal, luminal ER, and luminal ER+ subpopulations. 5,000 cells
d after 12–14 days.
ithelial) or the luminal ER fraction transduced with control (shScr) or Lyn
owth was assessed after 12–14 days. Representative images, left (scale bar,
ontrol shRNA (shScr) or shRNA against LYN (shLyn1 and shLyn2). Transduced
12 days of culture. Representative images of acinar structures (day 12) derived
CellTiterGlo quantitation and assessment of LYN knockdown by western blot
shLyn1, or shLyn2 knockdown MCF10A cells at day 4 of culture in 3D with
d SD (n = 3; two-tailed unpaired t tests) except for gene expression analysis by
f real-time RT-PCR data was determined from confidence intervals; n = 3 in-
et al., 2007). *p < 0.05; **p < 0.01; ***p < 0.001. See also Figures S1–S3.
(legend on next page)
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(Figure 3H). Upon orthotopic cell injection in immunodeficient
mice, administration of doxycycline resulted in a significant
decrease in the growth of tumors derived from cells carrying
inducible anti-Lyn shRNA (Figure 3I). Staining of tumor sections
for the mitotic cell marker phospho-H3 revealed a reduction in
the number of mitotic cells in samples from doxycycline-treated
shLyn tumors compared with controls (Figure S3I). Therefore,
LYN kinase depletion suppresses Brca1 mammary tumor cell
growth both in vitro and in vivo.
Brca1 Depletion Leads to Upregulation of LYN Kinase
Activity in a PIN1-Dependent Manner
Our data show that in normal mammary epithelial cells, LYN ki-
nase activity is under the strict control of the c-KIT receptor,
whereas in Brca1 mutant tumor cells, LYN functions indepen-
dently of c-KIT.We hypothesized that inactivation ofBrca1might
contribute to dysregulation of LYN kinase activity. First, we
analyzed a panel of TNBC cell lines for LYN and phospho-
LYN (Y397) levels. Three of the lines (MDA-MB-436, SUM-149,
and HCC1937) carry inactivating BRCA1 mutations, one
(HCC38) has BRCA1 promoter methylation, four (MDA-MB-
157, HCC1806, MDA-MB-468, and HCC70) have been reported
as having low BRCA1 expression (Buckley et al., 2016; Garcia
et al., 2011; Gong et al., 2015; Li et al., 2013), and six (MDA-
MB-231, MDA-MB-453, BT-20, BT-549, HCC1143, and
HCC1187) are BRCA1 wild-type. Total LYN levels were variable
across the lines; however, when phospho-LYN levels were
normalized to total LYN, TNBC cells with defective BRCA1 had
significantly higher levels of phospho-LYN than those of wild-
type cells (Figure 4A). Furthermore, Brca1 knockdown in primary
(normal) mouse mammary epithelial cells resulted in increased
LYN phosphorylation but unchanged c-KIT phosphorylationFigure 3. LYN Activity Is Required for Growth of Brca1 Tumor Cells
(A) Primary cells isolated from three distinct BlgCre Brca1fl/fl p53+/ mouse mam
(shLyn1 and shLyn2) lentiviruses, seeded at low density in adherent conditions (2D
by absorbance measurement following solubilization of the dye. Representative
(B) shScr-, shLyn1-, or shLyn2-transduced BlgCre Brca1fl/fl p53+/ tumor cells (1–
cell number assessed at day 5 of culture relative to shScr cells.
(C) Ki67 immunofluorescence staining (green) of control (shScr)- and shLyn-tran
transduction. Representative images and quantification of the percentage of Ki6
(D) Primary BlgCre Brca1fl/fl p53+/ mouse mammary tumor cells were transduce
empty expression vectors (shLyn), or shLyn and expression vectors carrying eithe
LYNA*WT) or a kinase-dead LYNA mutant (shLyn + LYNA*KD). LYN protein level
number assessed at day 5 of culture relative to shScr cells.
(E) HCC1937 cells were transduced with control (shScr) or Lyn knockdown (shLyn
after 6 days.
(F) shScr-, shLyn1-, or shLyn2-transducedHCC1937 cells were seeded at low den
(A). Representative images show tumor cell colonies at day 7 of culture.
(G) BRCA1 mutant PDX-derived cells (BCM 3887) were transduced with control (
viability after 10–12 days of culture in 3D on Matrigel.
(H) Primary mouse BlgCre Brca1fl/fl p53+/mammary tumor cells were transduced
shLyn) lentiviruses. Lyn levels were determined in cells transduced with either ind
(DOX) by qRT-PCR relative to shScr cells without DOX.
(I) 250,000 inducible shScr- or shLyn-transduced cells were orthotopically injected
DOX treatment or normal diet, and tumor growth was monitored. Tumor volumes
growth curves (mean ± SEM) and representative images of endpoint tumors are
Blots are representative of three independent experiments. Unless otherwise state
cell isolations from 3 PDX implants in 3 mice; two-tailed unpaired t tests), excep
confidence intervals; significance of real-time RT-PCR data was determined from
replicates per sample) (Cumming et al., 2007). *p < 0.05; **p < 0.01; ***p < 0.001
3680 Cell Reports 25, 3674–3692, December 26, 2018(Figure 4B). Conversely, forced overexpression of hemaggluti-
nin-tagged BRCA1 (HA-BRCA1) in primary mammary epithelial
cells suppressed LYN phosphorylation (Figure 4C).
The prolyl isomerase PIN1 recognizes specific serine-proline
or threonine-proline sequences in proteins, changing the confor-
mation of the prolines within these sequences and resulting in
altered activity of the target protein (Zhou and Lu, 2016). LYN
contains potential PIN1 consensus target sequences (Pro197
and Pro229), and PIN1 is transcriptionally repressed by BRCA1
(MacLachlan et al., 2000). Therefore, we hypothesized that
increased LYN activity following BRCA1 inactivation or depletion
results from increased PIN1 levels and that PIN1 was activating
LYN. To test this, we first used phospho-protein arrays to
demonstrate that both BRCA1 overexpression and PIN1 knock-
down in MDA-MB-468 cells resulted in a significant reduction in
phosphorylation of LYN, but not its close family member SRC
(Figures S4A and S4B). Moreover, we confirmed that BRCA1
suppresses PIN1 expression by overexpressing BRCA1 in
MDA-MB-468 cells and showing that PIN1 mRNA levels were
reduced by approximately 50% (Figure S4C). We also compared
PIN1 levels in mouse Brca1 tumor cells and normal mousemam-
mary epithelium and confirmed that PIN1 levels were signifi-
cantly higher in the tumor cells (Figure S4D).
Next, we stained a tissue microarray consisting of 15 germline
BRCA1 mutant and 15 sporadic TNBC cases. Cases from
BRCA1 patients showed, overall, significantly more intense
PIN1 staining than did sporadic tumors (Figures 4D and 4E).
Given our findings that BRCA1 loss results in PIN1 upregulation,
we hypothesized that even in sporadic breast cancers not
linked to germline BRCA1 mutation but that have low
BRCA1 levels through other mechanisms, levels of BRCA1 and
PIN1 expression would be inversely correlated. We thereforemary tumors (1–3) were transduced with control (shScr) or Lyn knockdown
), and stained with crystal violet after 6 days. Viable cell density was determined
images of tumor cell colonies at day 6 of culture are shown.
3) seeded in Matrigel (3D) were assessed for growth after 6 days. Graphs show
sduced BlgCre Brca1fl/fl p53+/ tumor cells in 3D culture 6 days after lentiviral
7-positive cells (n = 3). Scale bar, 20 mm.
d with either lentiviral shScr and empty expression vectors (shScr), shLyn and
r an shLyn-resistant form (indicated by an asterisk) of wild-type LYNA (shLyn +
s determined by western blot 6 days after transduction. The graph shows cell
1 and shLyn2) lentiviruses and tested for LYN expression levels by western blot
sity in adherent conditions. Viable cell density was determined after 7 days as in
shScr) or LYN knockdown (shLyn1 and shLyn2) lentiviruses and tested for cell
with pHIV-RFP-Tet repressor and pSEW-GFP-TO-H1 (carrying either shScr or
ucible shScr or shLyn and in either the presence or the absence of doxycycline
into the fourth right mammary fat pad of nudemice. These were randomized to
were calculated from caliper measurements of tumor width and length. Tumor
shown.
d, quantitation is shown as mean and SD (n = 3; for PDX cell experiments n = 3
t for gene expression analysis by quantitative real-time RT-PCR (mean ± 95%
confidence intervals; n = 3 independent experiments for each of 3 technical
. See also Figure S3.
(legend on next page)
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investigated their expression patterns in sporadic TCGA breast
cancer cases and, consistent with our hypothesis, observed an
inverse correlation between BRCA1 and PIN1 expression levels
(Figure S4E).
To demonstrate a direct functional link between PIN1 expres-
sion and LYN activity, we knocked down PIN1 in primary mouse
Brca1 null cells (Figure 5A) and cells from a BRCA1 mutant hu-
man breast cancer cell line (HCC1937) (Figure 5B) and the
BRCA1 mutant PDX (Figure 5C). In all cases, knockdown of
PIN1 decreased active LYN phosphorylation and cell survival,
mimicking the effect of LYN knockdown, but it did not change
c-KIT phosphorylation.
To elucidate the relationship of LYN phosphorylation, PIN1,
and BRCA1, we silenced PIN1 in a broader panel of TNBC cell
lines. In HCC38, MDA-MB-436, HCC1395, and MDA-MB-468
cells (BRCA1 defective), PIN1 knockdown resulted in decreased
LYN Y397 phosphorylation (Figures S4F–S4J). In HCC1187 cells
(BRCA1wild-type), PIN1 knockdown did not affect phosphoryla-
tion (Figure S4J); in this line, LYN was still regulated by c-KIT
(Figure S3A).
Co-immunoprecipitation (coIP) demonstrated that in mouse
Brca1 null tumor cells, PIN1 interacted with LYN (Figure 5D).
Furthermore, generation of mutants in putative PIN1 consensus
target sequences (Figure 5E) showed that proline-to-isoleucine
mutation of either residue 197 or both 197 and 229 resulted in
a significant increase in inhibitory LYN phosphorylation at the
Y508 site (Figure 5F).
We next assessed whether the PIN1-LYN regulatory mecha-
nism is likely to be more widely applicable than just to BRCA1
breast cancer. We therefore knocked down PIN1 in BRCA2
null mammary epithelial cells and in a panel of BRCA1 and
BRCA2 null ovarian cancer cells. PIN1 knockdown significantly
reduced LYN Y397 phosphorylation in a human BRCA2 mutant
breast cancer cell line (Figure S5A) and in primary mouse
Brca2 null tumor cells (Figure S5B). However, knockdown of
Brca2 in primary normal mouse mammary cells did not alter
PIN1 or phospho-LYN levels (Figure S5C). PIN1 knockdown sup-
pressed LYN Y397 phosphorylation in COV 362 cells (BRCA1
mutant ovarian carcinoma) (Figure S5D) and PEO-1 and PEO-4
cells (BRCA2 mutant ovarian carcinoma) (Figures S5E and
S5F), but not in KURAMOCHI cells (BRCA2 mutant ovarian car-
cinoma) (Figure S5G). Therefore, regulation of LYN by PIN1 is a
general (but not universal) mechanism, but PIN1 is not regulated
by BRCA2. These findings are consistent with transcriptional ac-Figure 4. LYN Activity Is Regulated by BRCA1 via the Prolyl Isomerase
(A) Protein extracts from TNBC cells with either wild-type BRCA1 or impaired BRC
GAPDH levels by western blot. Scatterplot shows quantification of p-LYN levels
(B) Primary mouse mammary organoids were transduced with control (shScr) or
PCR relative to comparator shScr cells (left). shScr and shBrca1 cells were assess
by western blot after 4 days (middle).
(C) Western blot analysis and quantitation of LYN autophosphorylation levels in p
BRCA1 (HA BRCA1) expression lentiviruses.
(D) Examples of PIN1 immunohistochemistry scores in breast cancer TMAs: (i) 0
nuclei. Scale bar in main panels, 500 mm; scale bar in inset, 50 mm.
(E) Quantitation of PIN1 scoring in BRCA1 mutant and sporadic TNBC TMAs.
Blots in (B) and (C) are representative of three independent experiments. Quantitat
expression analysis by quantitative real-time RT-PCR (mean ± 95%confidence int
intervals; n = 3 independent experiments for each of 3 technical replicates per s
3682 Cell Reports 25, 3674–3692, December 26, 2018tivity of BRCA1 being involved in PIN1 regulation, as previously
shown (MacLachlan et al., 2000).
To further investigate the involvement of specific BRCA1 func-
tional domains in the regulation of the PIN1-LYN axis, and the
possibility that different clinically relevant BRCA1 mutants may
have different effects on this axis, we re-expressed either the
wild-type BRCA1 or clinically relevant BRCA1missense mutants
(C61G in the RING domain, L1407P in the CCmotif, and A1708E
in the BRCT domain) (Anantha et al., 2017) in the HCC1937
human BRCA1-deficient breast cancer cell line. We found that
re-expression of both wild-type and C61G mutant BRCA1 re-
sulted in both decreased PIN1 levels and decreased LYN phos-
phorylation, while expression of the L1407P and A1708E muta-
tions showed no significant differences compared to control
BRCA1 mutant cells (Figure 5G). Therefore, mutation of the
N-terminal RING domain (which disrupts binding to BARD1)
does not alter the ability of BRCA1 to suppress the PIN1-LYN
activation pathway. In contrast, mutation of the coiled-coil
domain, affecting PALB2 binding (suggested to be critical for
the activation of the BRCA1 transcriptional program, as well as
for DNA repair) (Anantha et al., 2017; Gardini et al., 2014), and
of the C-terminal BRCT domains, important for interactions
with Abraxas, BRIP1, and CtIP (Anantha et al., 2017) and known
to be important for BRCA1 transcriptional activity (Hayes et al.,
2000; Iofrida et al., 2012), result in elevated levels of PIN1 and
LYN activation. These support a model in which the transcrip-
tional activity of BRCA1 is critical in the control of PIN1-LYN
pathway activation.
Having established the BRCA1-PIN1-LYN axis, and given the
important role of BRCA1 in repair of double-stranded DNA
breaks, we examined whether LYN activity could affect the
normal mammary cell response to DNA damage. Primary normal
mouse mammary epithelial cells expressing LYNA CA were
treated with the DNA damaging agent methyl methane sulfonate
(MMS), which causes double-stranded breaks. Expression of
LYNA CA led to a marked transient increase in Akt phosphoryla-
tion, suggesting elevated levels of survival signaling, and a signif-
icant reduction in cleaved PARP levels (Figure S6A) and TUNEL
staining (Figure S6B), both markers of apoptosis, after MMS
treatment relative to control cells. Consistent with this, levels of
cleaved caspase-3 were significantly reduced in normal mam-
mary cells expressing LYNA CA, compared to control cells,
following treatment with 10 mM cisplatin (Figure S6C) or expo-
sure to 10 Gy of ionizing radiation (Figure S6D).PIN1
A1 expression were analyzed for phospho-LYN (p-LYN) (Y397), total LYN, and
normalized to total LYN levels.
Brca1 knockdown (shBrca1) lentiviruses. Knockdown was assessed by qRT-
ed for levels of phospho-c-KIT (Y719), phospho-LYN (Y397), LYN, and GAPDH
rimary mouse mammary organoids transduced with control (Ctr) or HA-tagged
, (ii) 1, (iii) 2, (iv) 3, and (v) 4. DAB staining of PIN1, and blue counterstaining of
ion is shown asmean and SD (n = 3; two-tailed unpaired t tests) except for gene
ervals; significance of real-time RT-PCR data was determined from confidence
ample) (Cumming et al., 2007). *p < 0.05; **p < 0.01. See also Figure S4.
(legend on next page)
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LYNA Drives Breast Tumor Cell Aggressiveness
We next asked whether the two LYN isoforms, LYNA and LYNB
(shown in detail in Figure S7A), play different roles in breast can-
cer biology, independent of the BRCA1-PIN1-LYN axis. First, we
transiently expressedGFP-tagged variants of LYNA and LYNB in
MDA-MB-231 cells. After 48 hr, cells were fixed, counterstained
with DAPI, and analyzed by confocal microscopy. Both LYNA
and LYNB were predominantly membrane localized, with addi-
tional foci of intracellular staining, under these conditions
(Figure S7B).
Next, we used a LYNA-specific shRNA to knock down LYNA
expression in MDA-MB-231 cells. shLynA cells displayed an
approximately 60% reduction in LYNA protein levels compared
to control (shScr) cells (Figure 6A). LYNA knockdown resulted
in an overall decrease in cell proliferation (Figure 6A) and a strong
reduction in cell migration and invasion in vitro (Figure 6B). To
exclude the possibility that the impaired growth, migration, and
invasion of shLynA knockdown cells was due to a reduction in to-
tal LYN levels, rather than depletion of the LYNA form, and to
determine the specific contribution of each LYN variant to the
malignant behavior of the cells, we used a knockdown and
reconstitution approach. Total LYN was knocked down in
MDA-MB-231 cells, and then either a LYNA or a LYNB variant
(LYNA* or LYNB*) not targetable by shLyn was re-expressed.
We assessed cell growth and the ability of the cells to migrate
and invade relative to control cells. Total LYN knockdown led
to a decrease in cell growth, but this could be rescued by either
LYNA* or LYNB* (Figure 6C), indicating that these two distinct
LYN isoforms can compensate for each other in promoting tu-
mor cell growth. LYN knockdown significantly reduced the ability
of the cells to migrate and invade; this could be rescued by
LYNA*; however, LYNB* was unable to do so (Figure 6D). There-
fore, while both LYN isoforms promoted tumor cell growth, only
LYNA drove aggressive behavior in these cells.
To determine whether LYNA and LYNB may associate with
different protein partners, and whether this might explain their
different effects on migration and invasion, we carried out a
mass spectrometry analysis of proteins that interact with the
two isoforms. LYN was knocked down in MDA-MB-231 cells,
and then either LYNA* or LYNB* was re-expressed. We also ex-
pressed a LYNA* variant, LYNA*Y32F (Figure S7C). Y32 is locatedFigure 5. LYN Is Activated in BRCA1 Null Cells by the Prolyl Isomerase
(A–C) Primary cells from BlgCre Brca1fl/fl p53+/ mouse mammary tumors (A), h
PDX-derived cells (C) were transduced with control (shScr) or Pin1 knockdown (s
assessed for levels of PIN1, LYN, phospho-LYN (Y397), and c-KIT (Y719) (PDX s
quantitation of phospho-LYN (Y397) levels are shown. GAPDHwas used as loadin
tumor cells and HCC1937 cells were also seeded at low density in adherent condit
absorbance measurement following solubilization of the dye. PDX-derived transd
cell viability.
(D) Protein extracts from primary BlgCre Brca1fl/fl p53+/ mouse tumor cells tran
cipitation by anti-PIN1 or control (IgG) antibodies. Total extracts (input) and imm
(E) Schematic of LYN showing the position of PIN1 consensus recognition seque
(F) Representative western blot analysis of LYN phosphorylation levels at the neg
transduced with vectors carrying wild-type LYNA or LYNA proline mutants (LYN
(G)Western blot analysis of LYN autophosphorylation and PIN1 levels in human HC
tagged wild-type or mutant BRCA1 (C61G, A1708E, or L1407P).
Blots are representative of three independent experiments. Quantitation is show
***p < 0.001. See also Figures S5 and S6.
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reported as being regulated by epidermal growth factor (EGF)
signaling (Huang et al., 2013); if phosphorylation of this tyrosine
was required for the differential behavior of LYNA compared to
LYNB, then we would predict LYNA*Y32F would behave like
LYNB. Cultures were established in duplicate, and one set was
treated with EGF before lysis (Huang et al., 2013). LYN was
immunoprecipitated from these eight conditions (LYN KD,
LYNA*, LYNB*, and LYNA*Y32F; all ±EGF), and lysates were
analyzed by tandem mass tagging. The full results and differen-
tially enriched proteins are provided in Table S1. There was little
difference between the proteins that co-immunoprecipitated
with LYNA* and LYNA*Y32F, arguing against the hypothesis that
LYNA*Y32F was like LYNB (Figure S7D). The outcome of the anal-
ysis of the LYNA*EGF, LYNA*+EGF, LYNA*Y32FEGF, and
LYNA*Y32F+EGF pull-downs, four independent cell preparations,
was similar. Furthermore, the list of co-immunoprecipitated pro-
teins included eight previously characterized LYN-interacting
proteins (ANKRD54, LIMA1, HNRNPK, MYH9, STAT3, PRKDC,
EGFR, and HSP90AB1) (Hein et al., 2015; Hornbeck et al.,
2015; Huang et al., 2005; Kumar et al., 1998; Mertins et al.,
2016; Petschnigg et al., 2014; Taipale et al., 2012; Tauzin
et al., 2008; Van Seuningen et al., 1995).
By comparing LYN knockdown samples with LYNA*- and
LYNB*-expressing samples, several proteins were identified
that were differentially enriched in LYNA* samples. Using a cut-
off for analysis of proteins that were enriched >1.2-fold both in
the LYNA* pull-down compared to the LYN KD pull-down and
in the LYNA* pull-down compared to the LYNB* pull-down,
we identified 20 candidate LYNA-interacting proteins. We car-
ried out a gene ontology analysis using DAVID (Huang et al.,
2009) of the differentially interacting proteins to begin to under-
stand their functional significance. The list of proteins and the
results of this analysis are provided in Table S1. Six proteins
(ACTC1, ACTG2, KRT5, LIMA1, MYH3, and TUBA1A) are asso-
ciated with the cytoskeleton and its regulation, and two pro-
teins (LPXN and TNS1) are associated with integrins and cell
adhesion. These findings suggest that LYNA and LYNB may
interact differently with cell adhesions and the cytoskeleton,
potentially explaining the effects of LYNA on migration and
invasion.PIN1
uman HCC1937 BRCA1-deficient breast cancer cells (B), and BRCA1 mutant
hPin1#1 and shPin1#2) lentiviruses and lysed after 72 hr. Protein extracts were
amples were not probed for phospho-KIT). Representative western blots and
g control. shScr-, shPin1#1-, and shPin1#2-transducedBlgCre Brca1fl/fl p53+/
ions and stained with crystal violet after 6 days. Cell number was determined by
uced cells were cultured for 10–12 days in 3D on Matrigel and then assayed for
sduced with vectors carrying wild-type LYNA were subjected to immunopre-
unoprecipitates (IPs) were probed for PIN1 and LYN by western blot.
nces and the proline > isoleucine mutants generated.
ative regulatory phosphorylation site (Y508) in primary BlgCre Brca1fl/fl p53+/
P229I, LYN P197I, or LYN P197I P229I).
C1937 cells transduced with either control (Ctr) lentivirus or virus-carrying HA-
n as mean and SD (n = 3; two-tailed unpaired t tests). *p < 0.05; **p < 0.01;
(legend on next page)
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LYN Splicing Is Regulated by ESRP1
To determine what might regulate the balance between LYNA
and LYNB expression, we first examined Affymetrix Human
Exon 1.0ST array gene expression profiles of a breast cancer
cohort from Guy’s Hospital, London, and the TNBC subset of
these cancers. Cohorts were split into high-LYNA- and low-
LYNA-expressing tumors (i.e., above and below median ex-
pression of Affymetrix probe 3098998, uniquely targeting the
N-terminal region of LYNA), and the expression levels of 270
splicing regulators (the spliceosome) (Table S2) (Papasaikas
et al., 2015) were interrogated. We found that in ‘all breast can-
cers’ (Figure S8A) and the TNBC subset (Figure S8B), high-LYNA
tumors had significantly lower spliceosome levels than those of
low-LYNA tumors, indicating that splicing in general might be
compromised. Next, we examined the expression of a splicing
regulatory protein (ESRP1/RBM35A) with putative consensus
sequences in LYN intron 2 (Figure S8C). We found that ESRP1
levels were lower in high-LYNA breast cancers as a whole (Fig-
ure S8D) and in the high-LYNA TNBC subset (Figure S8E).
When ESRP1 was knocked down in MCF7 cells (Figure S8F),
which normally have a LYNA::B ratio of <2, the A::B ratio was
significantly increased to a mean of 2.5:1 (Figure 6E). Further-
more, when ESRP1 was overexpressed in MDA-MB-231 cells,
which normally have a LYNA::B ratio of >3, this ratio was signif-
icantly reduced (Figure 6F). Therefore, a decrease in the expres-
sion of the spliceosome in TNBC, and in particular ESRP1, could
result in an increased LYNA::B ratio.
Patients with a High Tumor LYNA::B Ratio Have Shorter
Survival
Because LYNA drives aggressive migratory and invasive proper-
ties in breast cancer, we asked whether total LYNA expression
levels, the relative amounts of LYNA and LYNB, or the LYNA::B
ratio might have prognostic potential.
First, we analyzed the relative expression of the LYNA and
LYNB isoforms in samples of human normal mammary tissue,
as well as triple-negative (TN) and ER+/PR+ primary breast can-
cer. The ratio of LYNA to LYNB transcripts was close to 1 in the
normal samples, but LYNA was preferentially expressed in
TNBC (Figure S9A). No significant difference in relative LYNA::
LYNB expression was observed in ER+/PR+ tumors comparedFigure 6. LYNA Drives Migration and Invasion in Breast Cancer Cells
(A) Western blot of LYN protein levels and growth of control (shScr) and LYNA kn
(B) Migration and invasion of shScr- and shLynA-MDA-MB-231 cells, assessed
tification of results compares the percentages of cells per field to shScr cells.
(C) Total LYN knockdown and LYNA or LYNB reconstitution using shLyn-resistan
cells forced to express either LYNA or LYNB and growth relative to shScr cells a
(D) Migration and invasion of control MDA-MB-231 (shScr) cells, LYN-depleted (
LYNB only (shLyn + LYNB*). Representative images show endpoint assays, and
cells.
(E) siControl (siCtr) and siESRP1 MCF7 cells were analyzed for LYNA::LYNB tr
quantitation) and western blot (bottom), respectively.
(F) MDA-MB-231 cells were transduced with control (Ctr) or FLAG-tagged ESRP1
(fold expression over comparator Ctr cells; upper left panel). Ctr and FLAG-ESRP
PCR (bottom panels), and LYN and ESRP1 protein levels were analyzed by west
Blots are representative of three independent experiments. Quantitation is shown
analysis by quantitative real-time RT-PCR (mean ± 95% confidence intervals; sig
n = 3 independent experiments for each of 3 technical replicates per sample) (Cum
3686 Cell Reports 25, 3674–3692, December 26, 2018to normal samples (Figure S9A). Similar results were observed
in a small panel of human breast cancer cell lines (basal ER
MDA-MB-231, MDA-MB-468, and HCC1143 and luminal ER+
MCF7) (Figure S9B). However, while we could be confident
that the tumor samples and cell lines in this analysis were pre-
dominantly composed of tumor cells, the normal tissue samples
had not been purified and likely contained a mixture of normal
epithelial cell populations and non-epithelial cells. Therefore,
for a more accurate assessment of the LYNA::B ratio in normal
human tissue, we used established flow cytometry protocols to
purify the basal, luminal progenitor, luminal ER+ differentiated,
and stromal cell populations from reduction mammoplasty sam-
ples from four individuals (Figures 7A–7C; Figure S10). Analysis
of LYNA::B demonstrated that the luminal progenitor population
had a significantly higher ratio compared with the other popula-
tions and that the LYNA::B ratio in normal cells was in a similar
range to that of the tumor samples.
To expand our analysis, we investigated a panel of breast can-
cer cell lines (Heiser et al., 2012) and the Guy’s Hospital TNBC-
enriched breast cancer cohort (Gazinska et al., 2013) for the
expression of the LYNA isoform using the Affymetrix probe
3098998. The LYNA sequence was significantly more highly ex-
pressed in basal and claudin-low cell lines than in luminal cell
lines (Figure S9C), and in the Guy’s dataset, it was more highly
expressed in tumors classified by PAM50 (Parker et al., 2009)
as basal (Figure S9D) or by immunohistochemistry as TNBC
(Figure S9E).
Next, we interrogated LYNA and LYNB expression in TCGA
breast cancer RNA sequencing (RNA-seq) data. Consistent with
the microarray-based results, LYNA was expressed more highly
in TNBC than in non-TNBC (p = 6.528e18, Wilcoxon rank-sum
test). Moreover, LYNB was higher in TNBC than non-TNBC
(p = 1.554e20, Wilcoxon rank-sum test), although it showed
overall lower expression levels thanLYNA (p =2.23e3,Wilcoxon
rank-sum test, for TNBC; p = 3.354e22, Wilcoxon rank-sum
tests, for non-TNBC) (Figure 7D). There was no difference in
LYNA::B ratio for normal breast tissue, TNBC, and non-TNBC in
the TCGA dataset (Figure 7E).
When we investigated the distributions of LYNA::B ratios
across all tumors, we noted that while most sample ratios were
in the range seen in the purified normal breast cells (Figure 7C),ockdown (shLynA) MDA-MB-231 cells relative to shScr cells at day 0.
by transwell assay. Representative images show endpoint assays, and quan-
t forms (LYNA/B*) in MDA-MB-231 cells. Western blot shows LYN knockdown
t day 0.
shLyn) cells, cells expressing LYNA only (shLyn + LYNA*), or cells expressing
quantification of results compares the percentages of cells per field to shScr
anscript ratio and LYN protein levels by semiquantitative RT-PCR (top, with
(FLAG-ESRP1) lentiviruses. ESRP1 overexpression was assessed by qRT-PCR
1 cells were analyzed for LYNA:LYNB transcript ratio by semiquantitative RT-
ern blot (upper right panel).
as mean and SD (n = 3; two-tailed unpaired t tests), except for gene expression
nificance of real-time RT-PCR data was determined from confidence intervals;
ming et al., 2007). *p < 0.05; **p < 0.01; ***p < 0.001. See also Figures S7 and S8.
(legend on next page)
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there was a distinct population of breast cancers with a log2
RSEM expression ratio of >7 (Figure 7F). When this population
was compared for time to breast cancer-specific death with
the remaining TCGA breast cancer cases, it had a shorter me-
dian time for survival (p = 0.032 for >7.3) (Figure 7G).
DISCUSSION
Although it has been previously reported that LYN is one of the
most highly expressed SFKs in the normal mammary gland
(Bach et al., 2017; Kendrick et al., 2008; Smart et al., 2011), its
function in this tissue has not previously been investigated.
LYN associates with c-KIT in hematopoietic cells and partici-
pates in numerous SCF-induced responses by promoting either
positive or negative downstream signaling, depending on cell
type and context (Shivakrupa and Linnekin, 2005). Our results
demonstrate that LYN is activated by c-KIT and is critical for
SCF:c-KIT-dependent phosphorylation of AKT in mammary pro-
genitors. However, given that LYN has been implicated in other
signaling pathways promoting cell survival and proliferation
(Shivakrupa and Linnekin, 2005), it cannot be ruled out that
additional pathways in mammary progenitors may be regulated
by LYN.
c-KIT+/ERmammary luminal progenitors are considered the
cell of origin of BRCA1-mutated and sporadic TNBC (Lim et al.,
2009; Molyneux et al., 2010). Although c-Kit is highly expressed
in Brca1 mutant mammary tumors (Regan et al., 2012; Smart
et al., 2011), as well as in a subset of breast cancers within the
TNBC group (Jansson et al., 2014), targeting this receptor has
not been an effective therapeutic approach (Yardley et al.,
2009). Our findings may at least partly explain why these trials
have failed. Although carriers of BRCA1 germline mutations
have an 80% lifetime risk of breast cancer, such cases make a
small contribution to breast cancer in the general population.
However, BRCA1 was found to be silenced through promoter
methylation in 14% of sporadic basal-like and 11% of non-
basal-like breast cancers, while in two special subtypes of
TNBC, medullary and metaplastic breast cancer, promoter
methylation was found in >60% of cases (Badve et al., 2011;
Turner et al., 2007). Furthermore, BRCA1 mRNA expression
was two-fold lower in TNBC compared to matched controls,
and this was suggested to depend on upregulation of ID4, a
negative regulator of BRCA1 transcription (Turner et al., 2007).Figure 7. The LYNA::LYNB Isoform Ratio Is Prognostic in Breast Canc
(A) Representative semiquantitative RT-PCR expression analysis of ESR1 and L
stromal cells, basal cells, luminal progenitors, and mature luminal populations (Irio
(B) Quantitation of ESR1 expression levels, confirmingESR1 is most highly expres
n = 3 independent cell preparations; unpaired two-tailed t test; **p < 0.01).
(C) Quantitation of the relative LYNA::B ratio (n = 4 independent cell preparations
(D) Expression of LYNA and LYNB isoforms in The Cancer Genome Atlas (TCGA) b
and non-TNBC (n = 470) tumors. Tumors are also color-coded based on their PA
(E) For each sample shown in (D), the LYNA::B ratio was established based on lo
samples derived from normal breast tissue (data also from TCGA), TNBC and no
(F) Density distributions of LYNA::B log2 RSEM expression ratios in the TCGA br
(G) Breast cancer-specific survival of patients based on LYNA::B isoform expr
boundary. The IHC phenotype of each tumor (where known) is indicated by the
survival time independent of the breast cancer subtype (Wilcoxon rank-sum test
See also Figures S9 and S10.
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anisms, such as activity of miRNAs (Garcia et al., 2011; Li et al.,
2013). Therefore, activation of the PIN1-LYN axis by BRCA1
downregulation is more widely applicable than to BRCA1 germ-
line mutation carriers alone.
PIN1 can be aberrantly activated in human cancers by various
mechanisms, including changes in transcription, translation,
and/or post-translational modifications (Zhou and Lu, 2016). In
addition to being a target for BRCA1 transcriptional activity,
PIN1 is a direct transcriptional target of E2F (Ryo et al., 2002).
PIN1mRNA stability is also inhibited bymiRNAs, while the phos-
phorylation and/or sumoylation status of specific PIN1 residues
has been reported to be critical for PIN1 substrate binding and/or
catalytic activity (Zhou and Lu, 2016).
PIN1 specifically catalyzes cis-trans proline isomerization
within phosphorylated Ser/Thr-Pro motifs with important effects
on phosphorylation-dependent signaling. Numerous oncogenes
and tumor suppressors are directly regulated by PIN1 (Zhou and
Lu, 2016), and here we show that PIN1 is an important contrib-
utor to LYN hyperactivation in BRCA1 mutant tumor cells.
Consistent with PIN1 substrates typically containing one or few
target motifs, LYN has only two putative PIN1 consensus sites
(Ser196-Pro197 and Ser228-Pro229). LYN phosphorylation at
Ser196 is only predicted, but phosphorylation at Ser228 has
been previously observed during cell-cycle progression (Daub
et al., 2008), although the specific kinase or kinases involved
are still unknown. These two sites are located in the SH2 domain
and in the SH2-Kinase domain linker segment, respectively,
which are involved in intra- and/or intermolecular interactions
critical for the regulation of the open-closed LYN conformation,
suggesting that local structural changes upon proline isomeriza-
tion are likely to affect LYN activation status. Our findings sug-
gest that regulation of LYN by PIN1 is a widely applicable
mechanism of regulation of this SFK but that SRC is not a target
of PIN1 (Figure S4B); whether other SFKs are PIN1 targets re-
mains to be investigated.
The link between BRCA1 loss of function and LYN activation
and the activation by LYN of signaling pathways that promote
cell survival, growth, and invasion are important findings. In
normal cells, the absence of functional BRCA1 results in
genomic instability, which leads to p53 activation, followed by
cell-cycle arrest and apoptosis (Roy et al., 2011), implying that
additional molecular alterations are required for BRCA1 mutanter
YN levels in breast cells from reduction mammoplasty tissue separated into
ndo et al., 2015). Plot is representative of outcomes of four independent sorts.
sed in themature luminal population (mean + SD relative tomature luminal cells;
; paired two-tailed t test; *p < 0.05) in breast cell populations.
reast cancer data split by immunohistochemistry (IHC)-defined TNBC (n = 112)
M50 molecular subtype.
g2 expression of LYNA over LYNB. The distribution of LYNA::B ratios among
n-TNBC were comparable when tested by Wilcoxon rank-sum test.
east cancer dataset. A LYNA::B ratio cutoff of 7.3 is indicated.
ession ratio from TCGA data in patient groups dichotomized at the 7.3 ratio
color of each data point. A high LYNA::B ratio selects patients with a shorter
).
cells to survive and undergo malignant transformation. Not
surprisingly, TP53 mutations are frequently present in BRCA1-
associatedmammary tumors (Roy et al., 2011). As LYN hyperac-
tivation suppressed cell death induced by DNA damage,
aberrant LYN activation following BRCA1 loss could facilitate
neoplastic progression, allowing BRCA1 loss-of-function cells
to survive long enough to accumulate TP53 genetic alterations.
Furthermore, activation of AKT downstream of LYN has been
linked to ubiquitination and degradation of the p53 protein
(Dos Santos et al., 2013; Iqbal et al., 2010), and this would enable
functional suppression of the p53 pathway in BRCA1 mutant
cells before genetic pathway suppression. There is some evi-
dence that LYN is generally anti-apoptotic (Aira et al., 2018),
and this warrants further investigation in breast cancer.
Alternative splicing is a critical post-transcriptional regulatory
mechanism for many cancer-associated genes (Bonomi et al.,
2013). LYN kinase exists as two isoforms, full-length LYN
(LYNA) and LYND25–45 (LYNB), differing by a 21-amino acid insert
found in the unique NH2-terminal domain (Alvarez-Errico et al.,
2010). We have found that in breast epithelial cells, the balance
between these transcripts is modulated by the splicing factor
ESRP1. LYN has not been found among the ESRP1-regulated
alternative spliced genes resulting from previous analyses (Sha-
piro et al., 2011; Warzecha et al., 2009, 2010), most likely due to
the lack of representative probe sets in the array platforms used
in those studies. Nevertheless, like LYN, known ESRP1 target
genes play a role in cell motility, cell adhesion, and/or epithe-
lial-mesenchymal transition (Shapiro et al., 2011; Warzecha
et al., 2009, 2010), indicating that co-regulation by ESRP1 of
splicing of transcripts for proteins that may function, together
with LYN, in a pro-migratory and invasive pathway in TNBC cells.
We find that patients with breast cancer with a high LYNA::
LYNB ratio have a shorter time to breast cancer death. Biologi-
cally, this clinical phenotype could be a result of LYNA conferring
migratory and invasive properties on breast cancer cells. How
alteration of the LYNA::LYNB ratio can generate signal outputs
leading to cancer cell aggressiveness remains to be fully defined.
Previous analysis of LYNA and LYNB function in mast cells re-
vealed the two isoforms associate differentially with phospho-
proteins (Alvarez-Errico et al., 2010), indicating that the 21-amino
acid sequence governs protein interactions. Moreover, LYNA
was more potent than LYNB in activating Phospholipase C
gamma (PLCg) and downstream Ca2+ signaling (Alvarez-Errico
et al., 2010). In addition, unlike LYNB, LYNA kinase activity can
be enhanced through phosphorylation by EGFR at a specific
tyrosine residue (Y32) within the 21-amino acid insert (Huang
et al., 2013). However, in an analysis of proteins differentially in-
teracting with the LYN isoforms, we saw little effect of either EGF
stimulation or Y32F mutation in the 21-amino acid insert. We did
find that LYNA interactedmore strongly with proteins associated
with the cytoskeleton, integrins, and cell adhesion, pointing to
differential effects of LYNA and LYNB onmigration and invasion.
This warrants further work.
Identification of patients who will respond to targeted, novel,
or repurposed therapies remains a major goal of clinical
research. Our findings demonstrate that patients with BRCA1
dysfunction or with a high LYNA::B isoform ratio would be partic-
ularly likely to benefit from specific therapies targeting LYN ki-nase. Furthermore, our findings on the key dual mechanisms of
LYN regulation, combined with knowledge of LYN interaction
partners, will enable rational design of new compounds to spe-
cifically block the oncogenic signaling driven by LYN without
the need to directly target the kinase domain, increasing treat-
ment specificity and reducing the likelihood of off-target effects.
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BRCA1 Sigma, Poole, Dorset, UK Cat# HPA034966, rabbit polyclonal
a6 Integrin eBioscience, Thermo Fisher Scientific,
Life Technologies, Paisley, UK
Cat# 14-0495-82, rat monoclonal
clone GoH3
cleaved PARP1 Cell Signaling Technology, Leiden,
the Netherlands
Cat# 9544, rabbit polyclonal
Ki-67 Vector Laboratories, Orton Southgate,
Peterborough, UK This antibody is no
longer available from this company.
Cat# VP-K452, mouse monoclonal
clone MM1
phospho-Histone H3 Cell Signaling Technology, Leiden,
the Netherlands
Cat# 9701, rabbit polyclonal
DYKDDDDK FLAG Tag Cell Signaling Technology, Leiden,
the Netherlands
Cat# 2368, rabbit polyclonal
HA Cell Signaling Technology, Leiden,
the Netherlands
Cat# 3724, rabbit monoclonal clone C29F4
GAPDH Merck Millipore, Watford, Hertfordshire, UK Cat# CB1001, mouse monoclonal
clone 6C5
a-tubulin Sigma, Poole, Dorset, UK Cat# T9026, mouse monoclonal
clone DM1A
HRP-conjugated anti-mouse IgG Sigma, Poole, Dorset, UK Cat# A4416, polyclonal
HRP-conjugated anti-rabbit IgG Sigma, Poole, Dorset, UK Cat# A6154, polyclonal
Alexa Fluor 488-conjugated anti-mouse IgG Life Technologies, Molecular Probes,
Paisley, UK
Cat# R37114, polyclonal
Alexa Fluor 488-conjugated anti-rat IgG Life Technologies, Molecular Probes,
Paisley, UK
Cat# A-11006, polyclonal
Biological Samples
RNA samples from human breast tumor tissue
and reduction mammoplasties
Breast Cancer Now Tissue Bank Anonymized
Normal breast tissue from women (n = 4;
aged 15, 24, 35, 39 years) undergoing reduction
mammoplasty with no previous history of
breast cancer
Cruz Roja, Clı´nica Indautxu Anonymized
Human breast cancer patient-derived
xenograft (PDX) BCM 3887
Baylor College of Medicine; an MTA may
be required for distribution of this material
Zhang et al., 2013
Human BRCA1 breast cancer tissuemicroarray Northern Ireland Biobank via Niamh
Buckley, Queen’s University Belfast; an
MTA may be required for distribution of this
material
N/A
Chemicals, Peptides, and Recombinant Proteins
Dasatinib Selleckchem, Stratech, Newmarket,
Suffolk, UK
Cat# S1021
Soluble murine SCF Peprotech, London, UK Cat# 250-03
Critical Commercial Assays
Proteome Profiler Human Phospho-Kinase
Array Kit
R&D Systems, Abingdon, Oxford, UK Cat# ARY003B
ApopTag Red In Situ Apoptosis Detection Kit Merck Millipore, Watford, Hertfordshire, UK Cat# S7165
Mouse Tumor Dissociation Kit for GentleMACS Miltenyi Biotec, Bisley, Surrey, UK Cat# 130-096-730
Experimental Models: Cell Lines
COV362 European Collection of Authenticated Cell
Cultures (ECACC)
Cat# 07071910
PEO1 European Collection of Authenticated Cell
Cultures (ECACC)
Cat# 10032308
(Continued on next page)
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PEO4 European Collection of Authenticated Cell
Cultures (ECACC)
Cat# 10032308
KURAMOCHI Japanese Collection of Research
Bioresources Cell Bank (JCRB).
Cat# JCRB0098
MCF-7 American Type Culture Collection (ATCC) Cat# ATCC HTB-22
MCF10A American Type Culture Collection (ATCC) Cat# ATCC CRL-10317
MDA-MB-157 American Type Culture Collection (ATCC) Cat# ATCC CRL-24
MDA-MB-231 American Type Culture Collection (ATCC) Cat# ATCC HTB-26
MDA-MB-436 American Type Culture Collection (ATCC) Cat# ATCC HTB-130
MDA-MB-453 American Type Culture Collection (ATCC) Cat# ATCC HTB-131
MDA-MB-468 American Type Culture Collection (ATCC) Cat# ATCC HTB-132
MDA-MB-468 EV (Empty vector) Niamh Buckley and Paul Mullan, Queens
University Belfast; an MTA may be required
for distribution of this material
N/A
MDA-MB-468 BR (BRCA1 overexpressing) Niamh Buckley and Paul Mullan, Queens
University Belfast; an MTA may be required
for distribution of this material
N/A
BT-20 American Type Culture Collection (ATCC) Cat# ATCC HTB-19
BT-549 American Type Culture Collection (ATCC) Cat# ATCC HTB-122
HCC38 American Type Culture Collection (ATCC) Cat# ATCC CRL-2314
HCC70 American Type Culture Collection (ATCC) Cat# ATCC CRL-2315
HCC1143 American Type Culture Collection (ATCC) Cat# ATCC CRL-2321
HCC1187 American Type Culture Collection (ATCC) Cat# ATCC CRL-2322
HCC1395 American Type Culture Collection (ATCC) Cat# ATCC CRL-2324
HCC1599 American Type Culture Collection (ATCC) Cat# ATCC CRL-2331
HCC1806 American Type Culture Collection (ATCC) Cat# ATCC CRL-2335
HCC1937 American Type Culture Collection (ATCC) Cat# ATCC CRL-2336
SUM-149 BioIVT, West Sussex, UK Cat# SUM-149PT
HEK293T From in-house frozen stocks; also available
from American Type Culture Collection
(ATCC)
ATCC Cat# CRL-11268
Experimental Models: Organisms/Strains
10 week old virgin female FVB mice Charles River, Margate, Kent, UK FVB/NCrl
Trp53tm1Brd Brca1tm1Aash Tg(LGB-cre)74Acl/J
(BlgCre Brca1fl/fl p53+/) mice
The Jackson Laboratory, Bar Harbor,
Maine, USA
Stock# 012620
BlgCre Brca2fl/fl p53fl/fl mice In house; an MTA may be required for
distribution of this material
Hay et al., 2009
NOD SCID g mice Charles River, Margate, Kent, UK NSG
Oligonucleotides
See Table S3 for details of oligos used for RT-
PCR, site directed mutagenesis, PCR cloning,
shRNA and siRNA knockdown, SYBR Green
qRTPCR oligos and TAQman qrtPCR assays
Non-Targeting siRNA Pool #1 Dharmacon, Cambridge, UK Cat# D-001206-13-05
ON-TARGETplus ESRP1 siRNA Dharmacon, Cambridge, UK Cat# L-020672-01-0005
Recombinant DNA
pEGFP-N3 Prof Vladimir Buchman, Cardiff University N/A
pENTRTM/H1/TO Thermo Fisher Scientific, Life Technologies,
Paisley, UK
Cat# K4920-00
ESRP1 cDNA Prof Klaus Holzmann, Institute of Cancer
Research, Medical University of Vienna
Leontieva and Ionov, 2009
(Continued on next page)
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pcDNATM6/TR (part of T-REx core kit) Thermo Fisher Scientific, Life Technologies,
Paisley, UK
Cat# K102002
pENTRTM/U6 (part of BLOCK-iT U6 RNAi Entry
Vector Kit)
Thermo Fisher Scientific, Life Technologies,
Paisley, UK
Cat# K4944-00
pHIV-H2BmRFP Addgene (https://www.addgene.org/) Cat# 18982
pLKO.1 MISSION TRC shRNA targeting mouse
Brca1
Sigma, Poole, Dorset, UK Cat# TRCN0000042559
pLKO.1 MISSION TRC shRNA targeting mouse
Kit#1
Sigma, Poole, Dorset, UK Cat# TRCN0000023672
pLKO.1 MISSION TRC shRNA targeting mouse
Kit#2
Sigma, Poole, Dorset, UK Cat# TRCN0000023673
pLKO.1 MISSION TRC shRNA targeting human
Lyn#1
Sigma, Poole, Dorset, UK Cat# TRCN0000230901
pLKO.1 MISSION TRC shRNA targeting human
Lyn#2
Sigma, Poole, Dorset, UK Cat# TRCN0000218210
pLKO.1 MISSION TRC shRNA targeting mouse
Lyn#1
Sigma, Poole, Dorset, UK Cat# TRCN0000023666
pLKO.1 MISSION TRC shRNA targeting mouse
shLyn#2
Sigma, Poole, Dorset, UK Cat# TRCN0000023668
pLKO.1 scramble (shScr) Addgene (https://www.addgene.org/) Cat# 26701
Gateway modified pWPI In house; an MTA may be required for
distribution of this material; pWPI
originally from Tronolabs
Regan et al., 2012
psPAX2 Addgene Cat# 12260
pMD2.G Addgene Cat# 12259
pSEW-GFP-TO-H1 In house; an MTA may be required for
distribution of this material
Regan et al., 2012
Software and Algorithms
Proteome Discoverer software v2.1 Thermo Fisher Scientific, Life Technologies,
Paisley, UK
Cat# OPTON-30795
Statistical analysis of tumor growth was
conducted using the glmer function for
generalized linear mixed models from the
lme4 package in R (version 3.2.2)
https://www.r-project.org/ Bates et al., 2015
Other
Gentle MACSTM Dissociator Miltenyi Biotec, Bisley, Surrey, UK Cat# 130-093-235
McIlwain Tissue Chopper Campden Instruments, Loughborough,
Leicestershire, UK
Cat# TC752CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the Lead Contact, Professor
Matt Smalley (SmalleyMJ@cardiff.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All animal work was carried out under UK Home Office project and personal licenses following local ethical approval and in accor-
dance with local and national guidelines, including ARRIVE guidelines. Normal primary mammary cells were prepared from fourth
mammary fat pads of 10 week-old virgin female FVB mice. The BlgCre Brca1fl/fl p53+/ and BlgCre Brca2fl/fl p53fl/fl mice and the tu-
mors they generate have been fully described previously (Hay et al., 2009; Molyneux et al., 2010).e4 Cell Reports 25, 3674–3692.e1–e10, December 26, 2018
Human Tissue
Normal breast tissue was obtained from women (n = 4; aged 15, 24, 35, 39 years) undergoing reduction mammoplasty with no pre-
vious history of breast cancer. Patients provided written informed consent and the procedures were approved by the local Hospital
Research Ethics Committee and by the ‘Ethics Committee of Clinical Investigation of Euskadi’.
The human breast cancer patient-derived xenograft (PDX) BCM 3887 derived from a patient with a BRCA1 mutation (Zhang et al.,
2013) was passaged in NOD scid gamma (NGS) mice.
The BRCA1 breast tumor (n = 15) and normal triple negative breast cancer (n = 15) tissue microarray was prepared by the Northern
Ireland Biobank under ethical approval number NIB17-0232.
RNA samples from human tumor tissue were obtained from Breast Cancer Now Tissue Bank. Normal tissue samples were from
reduction mammoplasties, selected to contain > 50% epithelium. All tumor samples (10 ER+PR+HER2- and 10 Triple Negative)
were from primary tumors of no specific type, grade III, from pre-menopausal patients.
Cell lines
Cells were maintained at 37C in a 5% CO2 atmosphere with the exception of MDA-MB-157, which were kept in L-15 medium with
10% FBS, streptomycin (100 ug/ml) and penicillin (100 U/ml) in a free gas exchange with atmospheric air.
MCF10A cells weremaintained in DMEM/F12 supplemented with 5%horse serum, 20 ng/ml EGF, 10 mg/ml insulin, 1 ng/ml cholera
toxin, 100 mg/ml hydrocortisone, 50 U/ml penicillin and 50 mg/ml streptomycin (growth medium). BT-549, KURAMOCHI, MCF-7,
MDA-MB-231 and MDA-MB-436 cells were cultured in RPMI 1640 medium with 10% FBS, L-glutamine (4 mM), streptomycin
(100 ug/ml) and penicillin (100 U/ml). HCC38, HCC-70, HCC1143, HCC1187, HCC-1395, HCC-1599, HCC1806 and HCC1937 cells
were cultured in modified RPMI-1640medium (ATCC 30-2001) supplemented with 10%FBS, streptomycin (100 ug/ml) and penicillin
(100U/ml). COV-362,MDA-MB-453 andMDA-MB-468 cells were grown in DMEMwith 10%FBS, streptomycin (100 ug/ml) and peni-
cillin (100 U/ml). HCC1937 and MDA-MB-468 cells stably overexpressing BRCA1 were previously generated (Buckley et al., 2011)
and were grown in the presence of puromycin (1 ug/ml). BT-20 cells were grown in MEM added with 10% FBS, non-essential amino
acids (0.1 mM), L-glutamine (2 mM), sodium pyruvate (1 mM), streptomycin (100 ug/ml) and penicillin (100 U/ml). PEO-1 and PEO-4
cells were cultured in RPMI 1640 medium with 10% FBS, L-glutamine (2 mM), sodium pyruvate (2mM) streptomycin (100 ug/ml) and
penicillin (100 U/ml). SUM-149 cells were grown in Ham’s F-12 medium containing 5% FBS, HEPES (10 mM), insulin (5 ug/ml), hy-
drocortisone (1 ug/ml), streptomycin (100 ug/ml) and penicillin (100 U/ml). See Key Resources Table for more details.
METHOD DETAILS
Isolation of and culture of normal mouse mammary epithelial cells
All animal work was carried out under UK Home Office project and personal licenses following local ethical approval and in accor-
dance with local and national guidelines, including ARRIVE guidelines.
Single cells were prepared from fourth mammary fat pads of humanely killed 10 week-old virgin female FVB mice. Intramammary
lymph nodes were removed prior to tissue collection. Fat pads were finely minced on a McIlwain Tissue Chopper and then digested
for 1 hr at 37C in 3 mg/ml collagenase A / 1.5 mg/ml trypsin (both from Sigma, Poole Dorset, UK) in serum-free L15 medium
(ThermoFisher Scientific, Life Technologies, Paisley, UK) with gentle rotation. Tissue fragments (‘organoids’) released from the fat
pad were washed and then incubated for 5 min in Red Blood Cell Lysis buffer (Sigma), washed and then plated for 1 hr at 37C in
DMEM/10%FBS (ThermoFisher) to partially purify fibroblasts by differential attachment. Organoids were then poured off, pelleted,
washed twice with versene (ThermoFisher) and then incubated for 15 min in serum-free Joklik’s Low Calcium medium (Sigma) at
37C. They were then pelleted and resuspended in 2mls of 0.25% trypsin / 0.02% EDTA in HBSS (Sigma) and incubated for two
min 37C to release single epithelial cells. 5 ml of 5 mg/ml DNase I (Sigma) in serum-free L15 was then added to digest DNA liberated
from any lysed cells. Single epithelial cells were then pelleted and washed in L15/10% FBS (ThermoFisher Scientific, Life Technol-
ogies, Paisley, UK) and then resuspended at 106 cells/ml in L15/10% FBS (Regan et al., 2012; Smalley, 2010; Smalley et al., 2012).
Cell suspensions were stained with combinations of anti-CD24-FITC (1.0 mg/ml; BD Biosciences, Oxford, UK), anti-CD45-PE-Cy7
(1.0 mg/ml; BD Biosciences), anti-Sca-1-APC (1.0 mg/ml; eBioscience, Hatfield, UK) or anti-Sca-1-PE (1.0 mg/ml; BD Biosciences)
antibodies and DAPI. Cells were then sorted on a FACSAria flow cytometer (BD Biosciences) excluding non-single cells by Time-
Of-Flight analysis, dead cells by DAPI staining and leukocytes by CD45 staining. Basal mammary epithelial cells were defined as
CD24+/Low Sca-1Negative. Luminal ER negative progenitor cells were defined as CD24+/High Sca-1Negative. Luminal ER positive differ-
entiated cells were defined as CD24+/High Sca-1Positive. Cells incubated in non-specific IgG were used to set the limits of negative and
positive staining for each antibody (Regan et al., 2012; Smalley, 2010; Smalley et al., 2012).
For 3D cultures, cells were resuspended in complete growthmedium (DMEM:F12with 10%FBS (ThermoFisher Scientific), 5 ug/ml
insulin (Sigma, Poole, UK), 10 ng/ml cholera toxin (Sigma) and 10 ng/ml epidermal growth factor) supplemented with 2.5% growth
factor reduced Matrigel (BD Biosciences, Oxford, UK) and plated in 96- or 48- well plates onto Matrigel (40 ul or 100 ul per well,
respectively). Cultures were maintained at 37 C in a 5% CO2/5%O2 atmosphere in a Galaxy 170R incubator (New Brunswick,
Eppendorf, Stevenage, UK). Stimulation with soluble murine SCF (Peprotech, London, UK) (100 ng/ml) and treatment with anti-
c-Kit (ACK2) or IgG isotype control antibodies (50 ug/ml) were carried out after starving cells for 12 hr.
Phase-contrast images were taken using a Leica MI6000B microscope (10X PH1 objective) and the LAS AF software.Cell Reports 25, 3674–3692.e1–e10, December 26, 2018 e5
Preparation and flow cytometric separation of normal breast cells from reduction mammoplasty
Normal breast tissue was obtained from pre-menopausal women undergoing reduction mammoplasty, with no previous history of
breast cancer, who gave their informed consent. All samples were confirmed by histopathological examination to be free of malig-
nancy. Immediately upon arrival at the laboratory, breast tissue was cut up manually into small pieces (approximately 0.5 cm cubed).
Breast material was incubated in an equal volume of Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO) supplemented with 5%
fetal calf serum (FCS) and collagenase (Type I, Sigma) to a final concentration of 0.2 mg/ml, and digested (while shaking) overnight at
37C. Following enzyme digestion, breast cells were washed and the organoids separated from any undigested material. The orga-
noids were then isolated from blood cells, fibroblasts, and endothelial cells by sequential filtration and back flushing from 140 and
53 mm pore size polyester monofilament meshes. Organoids were then disaggregated with 0.05% trypsin-EDTA and finally filtered
through a 40 mmsieve (BD) to yield a predominantly single cell suspension. Cells were immediately processed for flow cytometric cell
sorting on the basis of CD49f, ESA and 7-AAD staining (see Figure 7 and Figure S10) (Iriondo et al., 2015).
For CD49f/ESA staining, FITC-conjugated anti-ESA antibody and APC-conjugated anti-CD49f antibody were used (see Key
Resources Table). In all cases, control samples were stained with isotype-matched control antibodies; the viability dye 7-aminoac-
tinomycin D (7AAD) (BD) was used for dead cell exclusion and fluorescence minus one (FMO) controls were used to define the gates
(Iriondo et al., 2015). In all cases, cells were analyzed and sorted using a FACSAria (Becton Dickinson) flow cytometer. Data were
analyzed using FACSDiva software.
Primary tumor cell isolation and culture
Primary epithelial cells (from three distinct tumors (namely #1, #2, #3) from each mouse model or from three PDX implants) were ob-
tained using the gentle MACSTM Dissociator and Mouse Tumor dissociation kit (Miltenyi Biotec, Bisley, Surrey, UK) following the
manufacturer’s recommendations using the protocol for ‘Dissociation of Tough Tumors’ for mouse tumors and the protocol for
‘Dissociation of Soft andMedium Tumors’ for the PDX. To ensure efficient dissociation volumes of Enzyme D, Enzyme R and Enzyme
A were scaled up according to the size of the tumor piece (100 mL, 50 mL and 12.5 mL respectively per each 0.5 cm3). The optional
steps - the short spin for collection of the dissociatedmaterial at the bottom of theMACS tube and red blood cell lysis - were included
in the procedure.
Mouse cells were cultured in complete growthmedium in 2D adherent conditions for expansion or in 3D for functional studies. Cells
up to passage 5 were used for all the experiments in this study. Freshly isolated human PDX cells were grown in HuMEC Ready Me-
dium (Thermo Fisher Scientific) in Matrigel in 3D. Cultures were maintained at 37C in a 5%CO2/5%O2 atmosphere in a Galaxy 170R
incubator (New Brunswick, Eppendorf).
Protein extraction and western blot analysis
3D cultured primary mammary cells were released from Matrigel using the BD cell recovery solution and lysed in Laemmli buffer.
Protein extracts were separated by SDS-PAGE, transferred to PVDF membranes (IPVH00010, Merck Millipore, Hertfordshire, UK)
and immunoblotted with antibodies detailed in the Key Resources Table. GAPDH or alpha-tubulin were used as loading controls.
Resulting immunocomplexes were detected by HRP-conjugated anti-mouse IgG or anti-rabbit IgG secondary antibodies and
enhanced chemiluminescent (ECL) reagents (WBLUF0100, Merck Millipore). Protein extracts (400 ug) from Ctr, BRCA1-, siCtr-
and siPin1-MDA-MB-468 cells were processed and analyzed for phosphorylation of LYN (Y397) and SRC (Y419) using the Human
Phospho-Kinase Antibody Array (R&D Systems) following the manufacturer’s instructions.
Immunoprecipitation (IP) LYN kinase assay
Once recovered from Matrigel, 3D cultured cells were lysed in RIPA buffer (50mM Tris/HCl, pH 7.5, 150mM NaCl, 1% Triton X-100,
1% Na deoxycolate, 0.1% SDS) supplemented with 1mM Na orthovanadate and protease inhibitor-cocktail (Roche, Burgess Hill,
West Sussex, UK). After centrifugation (14000 g for 10 min at 4C), supernatants (150 mg of protein per sample) were pre-cleared
with protein A-Sepharose beads (GE Healthcare, Cardiff, UK) for 45 min at 4C prior to incubation with anti-LYN antibodies (rabbit
polyclonal sc-15) for 2 hr at 4C. Immunocomplexes were pulled down after binding to protein A-Sepharose beads (GE Healthcare)
for 45 min at 4C and washed twice with 20 mM HEPES, pH 7.4, 5 mM MgCl2, 3 mM MnCl2 1mM, 1mM Na orthovanadate (kinase
buffer). Beads were then resuspended in 50 mL of kinase buffer with 2.75 mg of acid denatured enolase (Sigma), 5-10 mCi of g32P ATP
(PerkinElmer, Seer Green, Buckinghamshire, UK) and 1 mMcold ATP. After a 10min-incubation at 30C, the reaction was stopped by
adding 13 mL of 10mM ATP, 50 mM EDTA and samples were subjected to SDS-PAGE on a 10% acrylamide gel. Gels were fixed in
10%methanol/ 10% acetic acid solution, then dried and developed by autoradiography. Intensities of bands corresponding to phos-
phorylated enolase were measured using the ImageJ software.
LYN-PIN1 co-immunoprecipitation
Primary BlgCre Brca1fl/fl p53+/ mouse tumor cells were collected in cold PBS pH 8.3 buffer with 10 mM EDTA, 0.1% Tween 20,
10 mM Sodium Fluoride, 1 mM Sodium Orthovanadate, 10 mM Sodium Pyrophosphate, 100 mM b-Glycerophosphate, 2 mM
PMSF, complete Protease Inhibitors (Roche) and lysed by passing through a 26G needle. After centrifugation (14000 g for 15 min
at 4C), supernatants (3-4 mg of protein) were pre-cleared with protein A-Sepharose beads (GE Healthcare) for 45 min at 4C prior
to incubation with anti-Pin1 (rabbit polyclonal (H-123), sc-15340, Santa Cruz) or control (IgG) antibodies overnight at 4C. Aftere6 Cell Reports 25, 3674–3692.e1–e10, December 26, 2018
incubation with protein A-Sepharose beads for 45 min at 4C, immunoprecipitates were pulled down by centrifugation (900 g for
5 min at 4C), washed five times with lysis buffer and eluted with Laemmli buffer. Samples were then resolved by SDS-PAGE on
10% polyacrylamide gels (15 3 15 cm). Western blot analysis was carried out as described above.
Gene expression analysis
With the exception of purified human primary cell populations (see below), RNA was extracted using the RNeasy Mini Kit (QIAGEN,
Manchester, UK) from freshly isolated primary mouse mammary cells and 2D cultured cells. Alternatively, Trizol reagent
(ThermoFisher Scientific, Paisley, UK) was used for RNA isolation from 3D cultured cells. cDNA synthesis was carried out using
QuantiTect Reverse Transcription Kit (QIAGEN) according to the manufacturer’s instructions.
Semiquantitative PCR reactions (28 cycles) were performed using GoTaq PCR Core System reagents (Promega, Southampton,
UK) and up to 120 ng of cDNA as template. Primers are listed in Table S3. PCR products were separated by electrophoresis on a 2%
agarose gel with the exception of c-Kit PCR products, which were resolved on a 4% agarose gel.
Quantitative real-time PCR (qPCR) was carried out using TAQMAN (Applied Biosystems, Life Technologies, Paisley, UK) Assays-
on-Demand probes or Fast SYBR green Master Mix (Table S3) on freshly isolated RNA. Results were analyzed using the D-DCt
method normalized to b-actin or GAPDH and expressed as relative to a comparator sample.
For normal primary human breast cell populations purified by flow cytometry, RNA was isolated using the Machery-Nagel
NucleoSpin RNA, according to instructions of the manufacturer. DNase-treated RNA was used to synthesize cDNA using
SuperScript VILO cDNA Synthesis Kit (Invitrogen, 11754050), following the manufacturer’s protocol. Semi-cuantitative-PCR was
performed using Phusion High-Fidelity DNA Polymerase (Thermofisher Scientific, F530S) and Deoxynucleotide (dNTP) Mix, PCR
Reagents (Sigma, D7295) on a MyCycler thermal cycler (Bio-Rad). 10 ng of cDNA was used as template and amplified using the
following conditions: 95C for 15 min, 22 cycles of amplification (95C for 30 s, 59C for 30 s, 72C for 1 min) and a final extension
at 72C for 5 min. Primer (Invitrogen) sequences can be found in the Table S3. Finally, PCR products were separated by 1.5%
agarose gel and stained with GelRed Nucleic Acid Gel Stain (Biotium). GAPDH was used as an internal control.
Cell viability and growth assays
Cell density in 2D cultures of primary cells andHCC1937was determined by absorbancemeasurement following fixation and staining
with crystal violet. CellTiterGlo cell viability reagent (Promega, Southampton, UK) was used to assess relative cell number of 3D
cultured primary cells andMDA-MB-231 cells. TheGelCount platform and software (Oxford Optronix, Oxford, UK) were used to auto-
matically determine the size of organoids grown in 3D.
Cell migration and invasion assay
Invasion and migration assays were performed using 24-well Transwell inserts (Corning, Amsterdam, the Netherlands) coated or not
withMatrigel, respectively. After 24 hr-starvation cells (75.000) were resuspended in serum-free (250 mL) medium and seeded into the
upper chamber. 750 mL of medium supplemented with 10% serum was added to the lower chamber. After 20 hr, cells on the lower
side of the insert were fixed, stained with crystal violet and counted under a light microscope.
siRNA Transfection
MDA-MB-468 cells were transfected with Pin1 or control siRNA (Table S3) using Lipofectamine RNAimax reagent (ThermoFisher
Scientific) in Opti-MEM serum-free medium (ThermoFisher Scientific). MCF7 cells were transfected with control (Non-Targeting
siRNA Pool #1, Dharmacon; see Key Resources Table) or ESRP1 siRNA (ON-TARGETplus, Dharmacon; see Key Resources Table)
using DharmaFECT 4 Transfection Reagent (Dharmacon). All analyses were performed 72 hr after transfection.
Lentiviral vectors and cell transduction
pLKO.1 lentiviral vectors carrying shRNA directed to Brca1, c-Kit and Lyn were selected from the corresponding pLKO.1 target gene
MISSION TRC shRNA sets (Sigma; see Key Resources Table). The c-Kit knockdown oligos target both c-Kit isoforms.
For LYNA, PIN1, c-KIT and Brca2, Pin1 knockdown experiments, DNA Oligonucleotide pairs for shRNA specifically targeting
LYNA, PIN1, Pin1 or shScr were ligated into the into the pENTRTM/U6Gateway system entry vector (ThermoFisher Scientific). Hairpin
sequenceswere verified and then transferred, together with theU6 promoter, into aGateway-modified pSEW lentiviral vector (Regan
et al., 2012) by LR reaction (ThermoFisher Scientific). ORFs for Lynmutants (LynACA and Lyn TK), mouse LynB, human LYNB, human
LYNA Y32F, LYN variants resistant to shLyn and human BRCA1 (C61G, L1407P, A1708E) mutants were generated using the
Quickchange Lightening site-directed mutagenesis kit (Agilent Technologies, Stockport, Cheshire, UK) according to the manufac-
turer’s instructions. Primers and templates used are listed in Table S3. Successful mutagenesis was verified by sequence analysis.
WT or mutagenized ORFs were then inserted into a Gateway modified pWPI lentiviral vector (Regan et al., 2012) by LR reaction. WPI
lentiviral vectors carrying HA-wt BRCA1, BRCA1mutants (C61G, L1407P, A1708E) or ESRP1-FLAGORFs were obtained following a
similar strategy (further details in Table S3; the ESRP1 plasmid was kindly provided by Prof Klaus Holzmann) (Leontieva and Ionov,
2009).
Viral supernatants were generated by co-transfection of the expression vector and two packaging vectors (psPAX2 and pMD2.G)
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48 and 72 hr after transfection, checked for absence of replication-competent virus and stored at 80C until use. Lentiviruses
derived from pWPI and pHIV-H2BmRFP plasmids were concentrated by ultracentrifugation (50,000g, 2 hr at 4C). Relative lentiviral
titer was determined by transducing NIH 3T3 cells using serial dilutions of the viral preparations. Freshly isolated primary cells were
resuspended in viral supernatant (shRNA-carrying vectors) or concentrated viral particles in growthmedium (overexpression vectors)
and plated on to Matrigel or plastic as required for the specific assay. After 24 hr, medium was replaced with fresh medium (Regan
et al., 2012). Puromycin (Sigma) (1.5 mg/ml) was added to culture medium of cells transduced PLKO.1 lentiviral vectors 36 hr after
infection.
Generation and expression of LYN-GFP fusion proteins
ORFs for human LYNA and LYNB were cloned into pEGFP-N3 (EcoRI/BamHI). Primers and templates used are listed in Table S3.
MDA-MB-231 cells were transiently transfected with pEGFP-N3-LYN A or pEGFP-N3-LYN B plasmids using Lipofectamine 3000
Reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions. After 48 hr cells were fixed, counterstained with
DAPI and analyzed by confocal microscopy.
In vitro and in vivo Dasatinib treatment
For in vitro experiments culture medium with a range of Dasatinib concentrations (Selleckchem, Stratech, Newmarket, Suffolk, UK)
was added to cells 24 hr after plating and replaced every other day. Sigmoidal curves fromdose-response data were generated using
Prism software.
For in vivo treatment, Dasatinib monohydrate (Selleckchem) was dissolved in DMSO at 20 mg/mL and stored in aliquots at20C.
Aliquots were thawed and diluted in 5.1% polyethylene glycol (PEG-400) and 5.1% Tween 80 (vehicle, VEH) before use. Mice were
treated with a single intraperitoneal (IP) injection of Dasatinib (DAS) (15 mg/Kg) daily. Control mice were treated with an equivalent
concentration of DMSO dissolved in vehicle. Caliper measurements of tumor width (W) and length (L) were recorded every other day
and tumor volumes were calculated using the formula (L x W2)/2).
In vivo conditional Lyn knockdown
Pairs of complementary DNA oligonucleotides (Table S3), encoding shLyn#2 (shLyn) or shScr, were annealed and cloned into a
pENTRTM/H1/TO vector (ThermoFisher Scientific). The H1/TO -shLyn or -shScr cassette was then transferred into a Gateway-modi-
fied pSEW lentiviral vector (Regan et al., 2012) via LR recombination. ORF of Tetracycline repressor (TetR) was amplified from
pcDNATM6/TR plasmid (ThermoFisher Scientific) (Table S3) and cloned into a pHIV-H2BmRFP lentiviral vector. Primary mouse
BlgCre Brca1fl/fl p53+/ mammary tumor cells (line #2) were transduced using pHIV-RFP-TetR and pSEW-GFP-TO-H1(-shScr
or -shLyn) lentiviral vectors. Cells positive for both GFP and RFP expression were then sorted on a FACSAria flow cytometer (BD
Biosciences) and assessed for Lyn knockdown in vitro in the absence or in the presence of doxycyline (0.5 ug/ml). 250,000 (shLyn-
or shScr-) cells were orthotopically injected into the fourth right mammary fat pad of nude mice. Mice were randomized to either a
control (DOX-) or a doxycicline (DOX+) diet (TD.09761, Harlan Teklad, Harlan, Indianapolis, USA). Tumor volumes were calculated
from caliper measurements of tumor width (W) and length (L) using the formula (L x W2)/2).
Immunofluorescence staining
For immunofluorescence analysis cells were grown in 8-well chamber slides (BD Biosciences) in 3D culture conditions (BD Biosci-
ences). Cells were fixed in 4% formalin for 20min andwashedwith PBS-glycine (0.7%) before blockingwith PBS/0.1%Bovine Serum
Albumin (BSA)/0.2% Triton X-100/0.05% Tween-20/10% goat serum for 1.5 hr.
Cultured MCF10A 3D acini were incubated for 2 hr with antibodies to Ki-67 (clone MM1) diluted 1:50 or to integrin-alpha6 (clone
GoH3) diluted 1:100 in blocking buffer prior to incubation with Alexa Fluor 488 Goat Anti-Mouse or Donkey Anti-Rat secondary an-
tibodies, respectively, for 1 hr. All incubation steps were carried out at room temperature. Counterstaining with DAPI was then fol-
lowed by mounting using the ProLong Antifade agent (ThermoFisher Scientific).
Indirect TUNEL was performed using The ApopTag Red In Situ Apoptosis Detection Kit (Merck Millipore) following the manufac-
turer’s protocol. Slides were analyzed on a Zeiss LSM 710 confocal microscope using a 20X objective.
Phospho-Histone H3 immunohistochemical staining
Immunohistochemistry was carried out following standard procedures. Fresh sections were cut from formalin-fixed and paraffin-
embedded tumor tissue. Dewaxed and re-hydrated slices underwent antigen retrieval in citrate buffer, pH 6.0 (Sigma) in a pressure
cooker for 5 min before incubation with a 3% hydrogen peroxyde solution for 20 min and then blocking in 1% BSA/0.1% Tween-20/
TBS for 1 hr. Incubation with anti-phospho-Histone H3 (S10) antibodies (rabbit polyclonal, #9701, Cell Signaling Technology; diluted
1:200 in blocking buffer) was performed overnight at 4C. Detection was carried out using the EnVision+System-HRP kit for rabbit
primary antibody (Dako, Ely, Cambridgeshire, UK). Sections were then counterstained with hematoxyilin and mounted. Images were
acquired using an Olympus BX43 microscope with a 20x/0.50 Ph1 objective.e8 Cell Reports 25, 3674–3692.e1–e10, December 26, 2018
PIN1 Immunohistochemistry and analysis of BRCA1 tumor TMA
PIN1 immunohistochemistry (IHC) was carried out by the Northern Ireland Biobank. Briefly, wax was removed from Formalin-Fixed
Paraffin-Embedded (FFPE) tissue by three washes with Bond Dewax solution (Leica, Milton Keynes, UK) at 72C, three washes with
alcohol, and three washes with Bond Wash solution (Leica). Proteins were prepared for antibody binding by incubating in Bond
Epitope Retrieval 1 solution (Leica) at 100C for 20 min. Slides were then washed three times with Bond Wash solution. Incubation
with primary antibody (anti-PIN1 Sc-46660) at 1:200 dilution was carried out for 15 min. The wash step was repeated before blocking
in peroxide for 5min, washing again, and incubating in Post Primary anti-mouse antibody for 8 min. Antibody detection with DABwas
carried out using the Bond Polymer Refine Detection kit (Leica) according to the manufacturer’s instructions, counterstained in he-
matoxylin and mounted.
PIN1 scoring was based on a scale of 0-4 where 0 represented no visible staining of PIN1, 1 represents low, 2 represents medium,
3 represents high and 4 represents very high, as per the examples in Figure 4. Each of three cores per patient was scored indepen-
dently; the highest score of the three was used as the overall score.
Isoform specific expression analysis by Affymetrix
The human LYN A isoform can be detected specifically by the microarray feature 3098998 on the Affymetrix Human Exon 1.0ST
arrays. To establish LYN A’s levels in human breast cancers, we extracted its isoform-specific expression across 177 previously
published breast carcinomas enriched for the triple negative phenotype (Braso´-Maristany et al., 2016; Gazinska et al., 2013)
(ArrayExpress accession number E-MTAB-570) and across a panel of breast cancer cell lines (Heiser et al., 2012). For each breast
cancer sample, immunohistochemistry-based and PAM50 derived breast cancer subtypes, as well as breast cancer cell line sub-
types were retrieved from the original publications, respectively (Gazinska et al., 2013; Heiser et al., 2012).
Isoform specific expression analysis by RNaseq
Level-3 RNaseq data and overall survival was downloaded from TCGA breast cancer (https://cancergenome.nih.gov/). LYNA and
LYNB isoforms were manually identified as uc003xsk.* and uc003xsl.* (see Figure S7A for details). Ratios were calculated using
raw RSEM values and log transformed for brevity. PAM50 classification was performed as described (Perou et al., 2000). Statistical
analyses and respective data plots were generated in R version 3.2.2.
LYN pull-down for Tandem Mass Tag (TMT) labeling
TMT enables robust quantitation and comparison by mass spectrometry of protein levels between samples. MDA-MB-231 (LYN KD,
LYN-A*, LYN-B*, LYN-YF*) cells were plated in T175 flasks and after two days were either serum-starved or left untreated overnight.
The following day starved cells were treated with 50 ng ul-1 EGF for two hr. Next, both treated and untreated cells were lysed in 1%
IGEPAL CA-630, 150 mM NaCl, 1mM MgCl2, 50 mM Tris pH 7.5, 5% glycerol, 10 mM Sodium Fluoride, 1 mM Sodium Orthovana-
date, 10 mM Sodium Pyrophosphate, 100 mM b-Glycerophosphate and Complete Protease inhibitor cocktail (Roche).
After centrifugation (14000 g for 15 min at 4C), cell lysates (3 mg of protein) were pre-cleared with protein A-Sepharose beads (GE
Healthcare) for 45 min at 4C prior to incubation with anti-LYN antibodies (rabbit polyclonal (44), sc-15, Santa Cruz) overnight at 4C.
After incubation with protein A-Sepharose beads for 45min at 4C, immunoprecipitates were pulled down by centrifugation (900 g for
5 min at 4C), washed three times with lysis buffer, twice with lysis buffer devoid of IGEPAL CA-630 and after removal of the super-
natants samples were stored at 80C until being processed for TMT labeling.
TMT Labeling and High pH reversed-phase chromatography
Pull-down samples were digested with trypsin while on the beads (2mg trypsin; 37C, overnight), labeled with Tandem Mass Tag
(TMT) ten plex reagents according to the manufacturer’s protocol (Thermo Fisher Scientific, Loughborough, LE11 5RG, UK) and
the labeled samples pooled.
The pooled sample was evaporated to dryness, resuspended in 5% formic acid and then desalted using a SepPak cartridge ac-
cording to themanufacturer’s instructions (Waters, Milford, Massachusetts, USA). Eluate from the SepPak cartridge was again evap-
orated to dryness and resuspended in buffer A (20mMammonium hydroxide, pH 10) prior to fractionation by high pH reversed-phase
chromatography using an Ultimate 3000 liquid chromatography system (Thermo Scientific). The sample was loaded onto an XBridge
BEH C18 Column (130A˚, 3.5 mm, 2.1 mm X 150 mm,Waters, UK) in buffer A and peptides eluted with an increasing gradient of buffer
B (20mMAmmoniumHydroxide in acetonitrile, pH 10) from0%–95%over 60min. The resulting fractionswere evaporated to dryness
and resuspended in 1% formic acid prior to analysis by nano-LCMSMS using an Orbitrap Fusion Tribrid mass spectrometer (Thermo
Scientific).
Nano-LC Mass Spectrometry
High pH RP fractions were further fractionated using an Ultimate 3000 nano-LC system in line with an Orbitrap Fusion Tribrid mass
spectrometer (Thermo Scientific). Peptides in 1% (vol/vol) formic acid were injected onto an Acclaim PepMap C18 nano-trap column
(Thermo Scientific). After washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides were resolved on a 250 mm 3
75 mm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over a 150 min organic gradient, using 7 gradient
segments (1%–6% solvent B over 1min., 6%–15% B over 58min., 15%–32%B over 58min., 32%–40%B over 5min., 40%–90%BCell Reports 25, 3674–3692.e1–e10, December 26, 2018 e9
over 1min., held at 90%B for 6min and then reduced to 1%B over 1min.) with a flow rate of 300 nL min1. Solvent A was 0.1% formic
acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic acid. Peptides were ionized by nano-electrospray ionization at
2.0kV using a stainless steel emitter with an internal diameter of 30 mm (Thermo Scientific) and a capillary temperature of 275C.
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by Xcalibur 2.0 software (Thermo Scien-
tific) and operated in data-dependent acquisitionmode using an SPS-MS3workflow. FTMS1 spectra were collected at a resolution of
120 000, with an automatic gain control (AGC) target of 200 000 and a max injection time of 50ms. Precursors were filtered with an
intensity threshold of 5000, according to charge state (to include charge states 2-7) and with monoisotopic precursor selection.
Previously interrogated precursors were excluded using a dynamic window (60 s ± 10ppm). The MS2 precursors were isolated
with a quadrupole mass filter set to a width of 1.2 m/z. ITMS2 spectra were collected with an AGC target of 10 000, max injection
time of 70ms and CID collision energy of 35%.
For FTMS3 analysis, the Orbitrap was operated at 50 000 resolution with an AGC target of 50 000 and a max injection time of
105ms. Precursors were fragmented by high energy collision dissociation (HCD) at a normalized collision energy of 60% to ensure
maximal TMT reporter ion yield. Synchronous Precursor Selection (SPS) was enabled to include up to 5 MS2 fragment ions in the
FTMS3 scan.
TMT Data Analysis
The raw data files were processed and quantified using ProteomeDiscoverer software v2.1 (Thermo Scientific) and searched against
the UniProt Human database (downloaded 14/09/17; 140000 sequences) plus LYNA and LYNB and LYNA_YF sequences using the
SEQUEST algorithm. Peptide precursor mass tolerance was set at 10ppm, and MS/MS tolerance was set at 0.6Da. Search criteria
included oxidation of methionine (+15.9949) as a variable modification and carbamidomethylation of cysteine (+57.0214) and the
addition of the TMT mass tag (+229.163) to peptide N-termini and lysine as fixed modifications. Searches were performed with
full tryptic digestion and a maximum of 2 missed cleavages were allowed. The reverse database search option was enabled and
the data were filtered to satisfy false discovery rate (FDR) of 5%.
QUANTIFICATION AND STATISTICAL ANALYSIS
Unless otherwise stated, blots shown are representative of three independent experiments. Unless otherwise stated, all quantitation
is shown as mean and SD from three independent experiments and statistical significance determined using two-tailed unpaired
t tests. Gene expression analysis by quantitative real-time rtPCR is shown as mean ± 95% confidence intervals from three indepen-
dent experiments, each of which was carried out using three technical replicates. Significance of real-time RT-PCR data was deter-
mined from confidence intervals (Cumming et al., 2007). *p < 0.05; **p < 0.01; ***p < 0.001.
Statistical analysis of tumor growth was conducted using the glmer function for generalized linear mixed models from the lme4
package (Bates et al., 2015) in the R software (version 3.2.2). The final model accounted for the change in tumor VOLUME with
time (DAY) and a DAY-by-TREATMENT interaction as fixed effects using variable random intercepts and slopes for each tumor
(TUMOUR_ID). This relationship was specified as glmer (VOLUME  DAY + DAY:TREATMENT + (DAYjfTUMOUR_ID), family =
Gaussian (link = ‘‘log). All modelling assumptions were confirmed to be reasonable on diagnostic residual plots.
Number of phospho-H3-positive cells in FFPE sections of grafted tumors was determined by using ImageJ image analysis soft-
ware (https://imagej.nih.gov/ij/). Automatic counting was performed on binary images (8-12 fields per tumor) after applying consec-
utive dilations to coalesce multiple dots within the same cell.
Band intensities on gels and western blots were also quantified using ImageJ.e10 Cell Reports 25, 3674–3692.e1–e10, December 26, 2018
